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Abstract
Fatigue was recently reported to be the largest predictor of poor health-related
quality of life (HRQOL) in children and adolescents with Duchenne muscular dystrophy
(DMD). The objectives of this thesis were to describe fatigue from patients’ and parents’
perspectives and to explore associations of patient characteristics with fatigue in children
and adolescents with DMD using a multicentre cross-sectional study design. Eligible
patients and their parents were identified via the Canadian Neuromuscular Disease Registry
and received mailed paper questionnaires. Children and adolescents with DMD
experienced greater fatigue compared to healthy controls from published data. Fatigue was
a significant issue in children and adolescents with DMD across all disease stages. Sleep
disturbance symptoms, depressive symptoms and functional ability were associated with
fatigue. Physical activity level was not associated with fatigue. These findings warrant
future research aimed at understanding the determinants of fatigue and developing
therapeutic strategies to reduce fatigue and improve HRQOL.
Keywords: Duchenne muscular dystrophy, children, adolescents, fatigue
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Chapter 1
1
1.1

Introduction
Thesis Overview
Duchenne muscular dystrophy (DMD) is the most common and severe form of

childhood muscular dystrophy, with an estimated incidence of 1 in 3600–6000 live male
births. DMD is an X-linked recessive disease caused by the absence of or defect in the
sarcolemmal protein dystrophin, ultimately resulting in progressive muscle degeneration
and loss of independent ambulation by 13 years of age. Additional musculoskeletal,
respiratory and cardiac complications emerge in patients as DMD advances. There is no
cure for DMD. Current therapeutic strategies aim to improve quality of life [1]. In a recent
study published by our group, fatigue was reported to be the largest predictor of poor
health-related quality of life (HRQOL) in children and adolescents with DMD, from both
patients’ and caregivers’ perspectives [2,3]. Fatigue is frequent and disabling in adults with
neuromuscular disorders, but not well characterized in children and adolescents with
neuromuscular disorders, including DMD [4]. Fatigue may be a modifiable factor, which
makes it a particularly important construct to study fully [5]. However, the pathogenesis of
fatigue in neuromuscular disorders is poorly understood and consequently, evidence
regarding the efficacy of non-pharmacological and pharmacological interventions for the
prevention and management of fatigue in patients with neuromuscular disorders is limited
and inconsistent [6,7]. To our knowledge, no studies have explored factors associated with
fatigue in children, adolescents or adults with DMD. Consequently, inferences from the
study of fatigue in other neuromuscular disorders and childhood chronic health conditions,
and a more clinically informed conceptualization of fatigue in DMD were required during
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the formulation of the thesis objectives. Identifying fatigue when present and
understanding the determinants of fatigue may facilitate the development of therapeutic
strategies to effectively reduce fatigue, and subsequently improve HRQOL in children and
adolescents with DMD. The aim of this thesis was to describe fatigue and to identify factors
associated with fatigue in children and adolescents with DMD, using a multi-centre crosssectional survey study design. The current chapter provides background knowledge on
fatigue and DMD, a proposed model of fatigue in children and adolescents with DMD, and
objectives of this thesis. Subsequent chapters provide a comprehensive literature review on
fatigue in DMD and related neuromuscular disorders (Chapter 2), followed by the methods
(Chapter 3), results (Chapter 4), and discussion (Chapter 5).
1.2

Fatigue
The feeling of fatigue is a universal phenomenon and can be a normal response to

physical and mental stress. However, fatigue is a frequent complaint secondary to physical
or psychiatric illnesses, and is consistently associated with decreased quality of life and
functioning across patient populations [8–11]. Fatigue may be acute and come on suddenly
or be experienced more chronically. In the case of neuromuscular disorders, it is generally
chronic, however, acute episodes of worsened fatigue may occur and be severely disabling
[12]. Fatigue is among the most disabling symptoms in adult neuromuscular disorders, but
not well studied in paediatric neuromuscular disorders [4,5]. This is worrisome because
fatigue has different implications in children compared with adults. Fatigue may limit
children’s participation in age-related recreational and school activities, and consequently
delay physical, cognitive, language, social and emotional development, which are already
problematic in children and adolescents with DMD [4,13]. In clinical practice, fatigue is
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recognized as a common symptom of paediatric chronic health conditions, including
neurologic disorders (cerebral palsy, multiple sclerosis, fibromyalgia, epilepsy and
traumatic brain injury), cancer, postural orthostatic tachycardia syndrome, juvenile
idiopathic arthritis, diabetes, inflammatory bowel disease and obesity [14]. However, data
on the mechanisms and management of fatigue in paediatric chronic health conditions are
limited, with most studies focusing on children with cancer [15].
A major challenge in studying fatigue is the lack of a commonly accepted definition.
Many studies fail to explicitly define fatigue, possibly due to the assumption that the term
is known to all. Among studies that have defined fatigue, there is a considerable range of
definitions [9,16]. Differences in reported prevalence of fatigue in neuromuscular disorders
may be due to different definitions and assessment methods [17]. In 2011, an expert
workshop was organized by the European Neuromuscular Centre (ENMC) to achieve a
consensus on the definition of fatigue in neuromuscular disorders, and to discuss possible
interventions. The definition of fatigue proposed by the ENMC workshop reads
“Subjective or experienced fatigue is a lack of energy or the existence of weakness or
exhaustion—mentally, physically or both.” [17]. In addition to subjective fatigue, the term
physiological fatigue or fatigability often appears in the body of literature relating to fatigue
in neuromuscular disorders. Physiological fatigue or fatigability refers to difficulty
maintaining physical or mental activity at a desired level and, in the case of physical
fatigability, appears to be related to muscle weakness. Physiological fatigability occurs in
a short period of time, while subjective fatigue may persist over several days to weeks.
Subjective fatigue and physiological fatigability are not necessarily correlated. Figure 1.1
describes a conceptual model of fatigue in neuromuscular disorders. Subjective fatigue and
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physiological fatigability both have a physical and mental component [16]. Subjective
fatigue is assessed using self-reported or parent proxy-reported questionnaires, which can
be unidimensional or multidimensional [8,14,16,17]. Physiological fatigability is assessed
objectively in a laboratory setting, using exercise protocols for physical fatigability and
reaction time protocols for mental fatigability [9,16]. Physical fatigability can originate at
the level of the central nervous system (upper motor neuron) or peripheral nervous system
(lower motor neuron, neuromuscular junction or muscle) [18,19].
The focus of this thesis is subjective fatigue. Subjective fatigue often overlaps with
sleep disturbance symptoms, such as excessive daytime sleepiness, or depressive
symptoms. Fatigue, sleep disturbance symptoms and depressive symptoms can occur
independently or co-exist and exacerbate one another in chronic health conditions. It is
important to distinguish fatigue from these other entities, as clear definitions in the research
and clinical realms are critical to accurately describe and measure these constructs, such
that interventions can be more specifically targeted to achieve satisfactory outcomes [4,19].
Fatigue implies mental or physical exhaustion, independent of exertion or amount of sleep,
whereas excessive daytime sleepiness implies a problem with the sleep-wake cycle [4].
Depression is characterized by a general lack of interest in daily activities that are normally
enjoyed. However, this motivational component is unaffected in fatigue. Fatigue may be
disease-related or induced by medical interventions [8]. Understanding the contributors to
and factors associated with fatigue in paediatric DMD is essential for comprehending this
complex symptom, and for ultimately developing effective therapeutic strategies for
reducing fatigue. Additionally, it is important to differentiate between disease-related and
treatment-induced fatigue. With the surge of novel therapeutics for DMD under
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development and clinical investigation, it is important for fatigue to be assessed both as a
potential marker of efficacy, given that an effective new therapy might reduce fatigue as it
improves motor function, or as a possible adverse effect when documenting safety
concerns. Moreover, the value of patient-reported outcomes in understanding the impact
and efficacy of a treatment is increasingly being recognized by regulatory authorities, such
as the U.S. Food and Drug Administration [20].

Fatigue

Subjective Fatigue

Physiological Fatigability

Assessed using unidimensional or
multidimensional questionnaires

Assessed using laboratory testing
(exercise protocols and reaction-time
protocols for physical and mental
fatigability, respectively)

Subjective Physical
Fatigue

Subjective Mental
Fatigue
Physical Fatigability

Central Origin
Upper motor neuron

Mental Fatigability

Peripheral Origin
Lower motor neuron,
neuromuscular
junction, muscle

Figure 1.1. A conceptual model of fatigue in neuromuscular disorders. Adapted from Lou.
Phys Med Rehabil Clin N Am. 2012;23:11–22.
1.3
1.3.1

Duchenne Muscular Dystrophy
Epidemiology
DMD is the most common form of inherited muscle disease in childhood [21]. A

systematic review and meta-analysis of population-based prevalence and incidence
estimates of DMD was recently conducted [22]. The pooled prevalence of DMD was 4.78
(95% CI: 1.94, 11.81) per 100,000 males worldwide. Among paediatric populations, the

6
prevalence was 12.57 (95% CI: 9.04, 17.46) per 100,000 males worldwide. Meta-analysis
was not performed on incidence estimates due to limited data and study heterogeneity. The
incidence of DMD ranged from 10.71 to 27.78 per 100,000 live born males per year
worldwide between the years 1986–1997. Prevalence and incidence studies of DMD were
limited to North American, European, African and Asian populations. However, the
majority of data was collected from European populations [22]. The incidence rate in the
Canadian population is estimated to be 1 per 3,600–4,700 live born males per year and has
remained relatively stable over time between the years 1969–2008 [23,24].
1.3.2

Pathogenesis
As an X-linked recessive disease, DMD primarily affects males. However,

approximately 8% of female carriers present with muscle weakness to some extent and are
designated as manifesting carriers [25]. DMD is caused by mutations in the DMD gene at
locus Xp21.2, which codes for the sarcolemmal protein dystrophin [26]. The DMD gene
contains 79 exons and seven promoters, which generate protein isoforms expressed in
various tissues [27]. The majority of cases are caused by deletions (~68%), followed by
small point mutations (~20%) and duplications (~11%), which disrupt the reading frame
or generate a premature stop codon in the protein-coding region of the DMD gene [28,29].
Consequently, the production of non-functional or truncated protein leads to dystrophin
deficiency in skeletal and cardiac muscle, as well as other tissues where dystrophin
isoforms are expressed, such as smooth muscle, brain, retina and kidney [30]. Normally,
dystrophin interacts with integral membrane proteins to form the dystrophin-glycoprotein
complex, which connects the inner cytoskeleton of skeletal and cardiac muscle fibres to
the extracellular matrix. The primary function of the dystrophin-glycoprotein complex is
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to stabilize the plasma membrane, protecting the muscle fibre from contraction-induced
damage. In addition to a structural role, the dystrophin-glycoprotein complex is
hypothesized to have a role in cellular signal transduction. In DMD, the absence of or
defect in dystrophin ultimately results in progressive muscle degeneration and additional
clinical manifestations that may contribute to fatigue [27,30–32].
1.3.3

Onset and Diagnosis
Children are typically diagnosed with DMD at 4–5 years of age, when their physical

ability diverges noticeably from their peers [28]. However, the diagnosis may be suspected
earlier due to delayed developmental motor or intellectual milestones [1,33]. Delayed
speech development is reported in 50–70% of children with DMD and may precede
concerns related to delayed motor development and muscle weakness. Although onset is
before school age in most cases, occasionally, a diagnosis is not made until 8–9 years of
age [34]. Weakness of pelvic girdle muscles results in a broad-based waddling gait, and
difficulty standing from a supine or sitting position, climbing stairs, running and jumping
[35,36]. Affected children also present with enlargement of the calf muscles during early
stages of the disease. Muscle enlargement is primarily due to excess adipose and fibrous
connective tissue and is therefore termed pseudohypertrophy [34]. In addition to abnormal
muscle function discovered during the medical history and physical examination, suspicion
of DMD may be triggered after the detection of elevated serum creatinine kinase or
transaminases (amino and alanine aminotransferases), which are indicative of muscle
damage [35,37].
Confirmation of the diagnosis is dependent on genetic testing. Initial genetic testing
aims to detect deletions and duplications, as these mutations account for most DMD cases.
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If no deletions or duplications are detected, sequencing of the whole DMD gene should be
performed to look for small point mutations [35]. In exceptional cases when no mutation
is detected in patients with a clear DMD phenotype, a muscle biopsy can be performed to
study dystrophin protein [28]. Establishing a genetic diagnosis is important for providing
optimal care in accordance with disease progression predicted by genotype-phenotype
associations, guiding genetic counselling for the family, and evaluating a patient’s
eligibility for emerging mutation-specific therapies [28].
1.3.4

Clinical Characteristics and Prognosis
In addition to progressive muscle degeneration, orthopaedic, respiratory and

cardiac complications emerge in children as DMD advances [1]. Affected children and
adolescents are also at increased risk for neurodevelopmental, emotional and behavioural
problems [38–40]. Muscle weakness, immobility, reduced respiratory and cardiac function,
and neuropsychiatric disturbances have all been reported to be associated with fatigue in
chronic health conditions, including neuromuscular disorders [5,41–48]. Prior to routine
glucocorticoid therapy and non-invasive ventilation (NIV), the mean age at death was 15
years and in 90% of cases, death occurred before the age of 20 years due to respiratory or
cardiac failure [49,50]. Improved medical management has prolonged survival with
patients now having a possible life expectancy into their fourth or fifth decade [34,51]. In
developed countries, mean age at death is now approximately 25 years [34,49,52].
Pulmonary infections and respiratory failure are the leading causes of death in DMD [53].
DMD is no longer considered purely a childhood disease, and fatigue experienced during
childhood and adolescence may impact outcomes in adulthood. By limiting participation
in age-related activities during childhood and adolescence, fatigue may impact
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developmental milestones and consequently impact social, educational and occupational
pursuits during adulthood [13,54].
Musculoskeletal Complications
Muscle weakness occurs bilaterally and symmetrically in DMD. During early
stages of the disease, lower limb muscles are affected more than upper limb muscles, and
proximal muscles more than distal muscles. Muscle weakness appears when skeletal
muscle has degenerated and been replaced by adipose and fibrous connective tissue. In
approximately 50% of affected children, walking is delayed until at least 18 months of age
[34]. In most cases, children are unable to run or jump properly [33]. Affected boys report
difficulty keeping up with their peers, and tenderness or stiffness after exercise, particularly
in their calf muscles [34]. In addition to a waddling gait, toe-walking is a frequent
complaint due to contractures of the Achilles tendon. During early stages of the disease,
weakness of the pelvic girdle muscles results in an anterior pelvic tilt, and consequently
progressive lumbar lordosis, an inward curvature of the lower spine, which can cause low
backache [34]. Muscle weakness continues and loss of independent ambulation typically
occurs by 13 years of age [55]. Initially, affected boys may only need to use a wheelchair
part-time, before becoming permanently confined to a wheelchair. An earlier age at loss of
ambulation is typically associated with poorer prognosis [34]. Transitioning to intermittent
wheelchair use has been reported to be associated with fatigue in children and adolescents
with DMD [3]. Upper extremity function declines during mid-teenage years and is
followed by an inability of affected boys to independently feed or care for themselves [56].
Muscle weakness and reduced functional ability secondary to muscle weakness have been
reported to be associated with fatigue in neuromuscular disorders, including
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facioscapulohumeral dystrophy, myotonic dystrophy, and hereditary motor and sensory
neuropathy type I [57]. In children and adolescents with DMD, objective measures of
functional ability, such as timed motor function tests, were weakly associated with fatigue
[58].
Around the time of loss of ambulation, most children with DMD develop some
degree of kyphoscoliosis—an abnormal spinal curvature in the coronal and sagittal planes.
Following its onset, kyphoscoliosis progresses rapidly and can impair unsupported sitting
ability, feeding and comfort, cause pain, and further deteriorate already compromised
respiratory and cardiac function of affected boys. By contributing to immobility and
respiratory and cardiac function decline, kyphoscoliosis may worsen fatigue [59–61].
Additionally, DMD is associated with reduced bone mineral density (osteopenia)
secondary to reduced load and immobility, and increased bone fragility (osteoporosis)
secondary to chronic glucocorticoid use. Poor bone health in DMD can further contribute
to immobility by increasing affected boys’ risk for bone fractures [62–65].
Respiratory Complications
Onset of respiratory function decline occurs between 9–11 years of age due to
progressive weakness of intercostal muscles and the diaphragm muscle [56]. Deterioration
of respiratory function is exacerbated by kyphoscoliosis [66]. Forced vital capacity, a
global index of respiratory function, is consistently above 70% in pre-adolescent ambulant
boys and declines linearly with age during adolescent years [34,50]. Respiratory muscle
weakness is associated with an ineffective cough, impaired airway clearance, pneumonia,
atelectasis, sleep disordered breathing and ultimately nocturnal, followed by daytime,
respiratory failure [50,64,67,68]. In neuromuscular disorders, fatigue may manifest as a
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symptom of respiratory failure [69]. Onset of respiratory failure can be predicted by a
forced vital capacity below 35% or an absolute forced vital capacity below 1 L. During
sleep, intercostal muscles are less active and diaphragmatic breathing alone cannot
sufficiently maintain normal gas exchange. Thus, early respiratory failure is characterized
by nocturnal hypoventilation, resulting in oxygen desaturation (hypoxemia) and
accumulation of carbon dioxide (hypercapnia), followed by restoration of normal blood
gas tension upon arousal. The early respiratory failure phase can last for several months.
However, when hypoxia and hypercapnia persist during the daytime, survival beyond 12
months is unlikely without the initiation of NIV [34,50,70].
Nocturnal and diurnal hypoventilation are frequently compounded with additional
sleep-related breathing disorders, such as obstructive sleep apnea (OSA) secondary to
oropharyngeal muscle weakness or weight gain associated with glucocorticoid therapy
[71]. In young boys with DMD, OSA in the absence of clinically significant
hypoventilation has also been reported. In affected boys, sleep-related breathing disorders
may co-exist with additional sleep disturbance symptoms including difficulty initiating or
maintaining sleep, sleep hyperhidrosis and excessive daytime sleepiness [72,73]. Bloetzer
et al. reported the need to be turned by a caregiver during the night as a predictor of sleep
disturbance symptoms in boys with DMD [72]. Muscle weakness and immobility may
therefore contribute to sleep disturbance symptoms. Sleep disturbance symptoms,
measured both subjectively by patient-report and objectively by polysomnography, have
been reported to contribute to fatigue in patient populations, such as myotonic dystrophy,
multiple sclerosis and cancer [7,74–82]. An association between sleep disturbance

12
symptoms and fatigue has also been reported in school age-children and paediatric patient
populations [78,79].
Cardiac Complications
Improved respiratory management has unmasked cardiomyopathy as a major
source of morbidity and mortality in DMD [83]. Premature death due to heart failure occurs
in 15–20% of patients [34]. Onset of cardiomyopathy occurs at a mean age of 14–15 years
and is a universal consequence by adulthood [84,85]. However, approximately 25% and
59% of affected boys present with asymptomatic cardiomyopathy at 6 and 10 years of age,
respectively [86]. Fibrosis caused by the degeneration of dystrophin-deficient
cardiomyocytes proceeds to progressive cardiomyopathy, characterized by left ventricular
systolic dysfunction with dilation [86–88]. Canadian Cardiovascular Society paediatric
heart failure guidelines define left ventricular systolic dysfunction as left ventricular
ejection fraction below 50% [89]. Because of physical activity limitations associated with
musculoskeletal weakness, exertional signs and symptoms of heart failure are often absent
despite myocardial disease progression [90]. Fibrosis of the conduction system, in addition
to the myocardium, has been demonstrated. Arrhythmias are seen in DMD; sinus
tachycardia is a common finding at disease onset [91]. In advanced cardiomyopathy,
patients may experience atrial fibrillation or flutter, ventricular fibrillation and ventricular
tachycardia [92]. Now that survival of patients with DMD is prolonged, the cause of death
in DMD is increasingly cardiac-related [34]. Cardiac dysfunction may be directly
associated with fatigue [43]. Evidence also suggests that cardiac dysfunction may
contribute to sleep disordered breathing. Conversely, sleep disordered breathing may
contribute to heart failure [93]. Cardiac dysfunction and sleep disordered breathing may
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therefore exacerbate one another and further contribute to fatigue in DMD. However,
because clinical manifestations of cardiomyopathy in DMD typically occur in young
adulthood [94], cardiac dysfunction may have a greater role in fatigue in adults with DMD
than in children or adolescents with DMD.
Neuropsychiatric Complications
The role of dystrophin isoforms in the central nervous system remains unclear,
however, it is recognized that DMD is associated with an increased risk for
neuropsychiatric disturbances [38]. Approximately one third of affected boys experience
learning difficulties [34]. Although there is considerable variability in intellectual ability
among affected boys, overall mean intellectual quotient scores are about one standard
deviation below the mean [95]. Working memory deficits have also been reported
[38,40,95]. Cognitive impairment in DMD is not progressive and does not correlate with
disease duration or severity [91]. Boys with DMD are reported to have a higher prevalence
of neurodevelopmental disorders, including autism spectrum disorder and attention deficit
hyperactivity disorder, than the general paediatric population [96,97]. Emotional and
behavioural problems, including depression, anxiety, aggression and oppositional defiant
disorder, are also frequently reported in affected boys [38,91]. Moreover, affected boys
may experience emotional and behavior problems as adverse effects of glucocorticoid use,
which is currently standard of care therapy in DMD [53]. An association between
depression and fatigue has been widely reported across paediatric and adult patient
populations, including neuromuscular disorders [12,44,47,98]. Depression has consistently
been described as the strongest correlate of cancer-related fatigue. The association between
depression and fatigue is hypothesized to be bidirectional, however, few longitudinal
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studies have examined directionality [99–101]. Moreover, depressive symptoms often coexist with sleep disturbance symptoms, and may therefore exacerbate one another to
contribute to fatigue [79,102,103].
1.3.5

Management
With the characterization of the DMD gene and its protein product, novel disease-

modifying therapies are under development and investigation. Disease-modifying
therapeutic strategies include agents to reduce muscle damage, promote muscle
regeneration following injury, or increase expression of functional dystrophin protein using
gene-therapy or RNA-based approaches [53,104,105]. To date, no disease-modifying
agents are licenced for use in routine clinical practice in Canada. Current therapeutic
strategies focus on prolonging ambulation, managing respiratory and cardiac
complications, and ultimately improving quality of life. Psychological, educational and
social needs of affected boys should also be considered at all stages of the disease [53].
International consensus-based recommendations on multidisciplinary standards of care in
DMD were published in 2010 [1,64].
Musculoskeletal Management
Glucocorticoids (prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day) are the
only pharmacological therapy that slow the decline in muscle strength and function [1,105].
Although the exact mechanism is unclear, glucocorticoids are hypothesized to act primarily
by reducing inflammation [105]. Glucocorticoid therapy is typically initiated between 5–8
years of age when the child’s motor development reaches a plateau phase, and is continued
indefinitely [1,26]. Long-term glucocorticoid use has been demonstrated to prolong
independent ambulation by 2–5 years, reduce the risk of scoliosis and the need for spinal
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fusion surgery, stabilize respiratory function and delay the need for NIV, stabilize cardiac
function, and improve survival and quality of life [52]. Deflazacort is as effective as
prednisone and associated with less weight gain, often making deflazacort the more
desirable option in Canada [106]. In addition to weight gain secondary to increased
appetite, adverse effects associated with chronic glucocorticoid use requiring proactive
prevention and management include: immunosuppression, growth failure, pubertal delay,
hirsutism, osteoporosis, hypertension, gastric ulceration, cataracts, and altered mood and
behaviour [53,65].
In conjunction with a neurologist or neuromuscular specialist, musculoskeletal care
should involve a physical therapist, physiatrist and orthopaedic surgeon. Active, activeassisted and passive stretching is recommended to prolong walking, and to prevent or
minimize contractures during ambulatory and non-ambulatory phases. Orthoses, standing
frames and walkers can be used to prolong ambulation and aid in standing. Lower-limb
contracture surgeries, and spinal fusion surgery to correct scoliosis and prevent further
deformity are considered on a case-by-case basis [53,64]. In boys with DMD, physical
activity level is largely related to musculoskeletal function. Physical activity level (overexertion or excessive rest) has been reported to be associated with fatigue, and exercise
therapy has been proposed as a treatment for fatigue [44,107–109]. However, evidence
supporting exercise therapy for the treatment of fatigue in neuromuscular disorders is
lacking [110].
Respiratory Management
Respiratory assessment should be conducted annually during early stages of the
disease, semi-annually following loss of ambulation, when forced vital capacity is below
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80% and/or 12 years of age, and before any surgical procedure. To improve airway
clearance and prevent pulmonary infections in patients with an ineffective cough,
mechanical insufflation-exsufflation machines can be used to assist coughing [68]. NIV,
particularly nocturnal nasal intermittent positive pressure ventilation, is the most effective
way to attenuate the decline in respiratory function. When patients progress to daytime
respiratory failure and require 24-hour ventilatory support, mouthpiece intermittent
positive pressure ventilation may be introduced [53,68]. In a recent study, comparing
respiratory management practices across Canada for children and adolescents with DMD,
variations in the timing and choice of tests for respiratory function and sleep disordered
breathing were reported. Polysomnography, overnight pulse oximetry or both were used to
detect sleep disordered breathing either routinely, at a certain age, or due to abnormal
pulmonary function tests [73]. However, the utility of overnight pulse oximetry alone for
the detection of sleep disordered breathing in neuromuscular disorders is unclear.
Moreover, the absence of abnormal pulmonary function tests and symptoms may not rule
out sleep disordered breathing. Therefore, routine polysomnography may be the most
effective screening practice for sleep disordered breathing and assisting in initiating NIV
[71,111]. Effective detection and treatment of sleep disordered breathing may subsequently
reduce fatigue.
Cardiac Management
Cardiac assessment should be conducted biannually until 10 years of age, annually
after 10 years of age, and before any surgical procedure [64]. Data regarding optimal
pharmacological regimens and when to initiate therapy to delay the onset of
cardiomyopathy in DMD are lacking [112]. Initiation of therapy with an angiotensin-
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converting enzyme inhibitor or angiotensin receptor blocker by 10 years of age is
recommended, however, it is unclear if earlier therapy is warranted. With further
deterioration, beta-adrenergic blocking agents are added, followed by diuretic agents at the
onset of symptomatic heart failure [92].
Neuropsychiatric Management
Neuropsychiatric assessment should be conducted around the time of diagnosis,
before entering school, and after a change in function. However, a brief evaluation of
patients’ emotional and coping status is recommended at every clinic visit. Speech
language therapy is necessary for younger boys with delayed speech development and
older boys with impaired speech intelligibility due to deteriorating oral muscle strength.
Development of an individual education plan is recommended for all boys with DMD to
address learning difficulties, physical activity limitations and accessibility issues in school.
Psychological and pharmacological therapies should be considered for moderate to severe
psychiatric symptoms, and prescribed according to standard practices and guidelines [64].
Antidepressants have been proposed as a possible treatment for fatigue. Studies evaluating
the efficacy of antidepressants to treat fatigue have reported conflicting results across
different patient populations, suggesting that the association between depression and
fatigue may be modified by disease-specific mechanisms [99,113–115].
1.4

A Proposed Model of Fatigue in Duchenne Muscular Dystrophy
Figure 1.2 presents a hypothesized model of fatigue in children and adolescents

with DMD. This model was developed based on the clinical characteristics and
management of DMD, in conjunction with the literature relating to fatigue in other
neuromuscular disorders and paediatric chronic health conditions. Sleep disturbance
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symptoms may be overlooked in the management of DMD [71], and variations exist in the
screening and management of sleep disordered breathing in children and adolescents with
DMD across Canada, between centres and sub-specialists (neurologist and respirologists)
[73]. Given the findings from the survey of respiratory management practices across
Canada for DMD patients [73], and recognizing that sleep may be a modifiable factor, the
need is clear for further study and consensus in this area to guide best clinical practices. In
addition to musculoskeletal, respiratory and cardiac characteristics being potential
predictors of fatigue in children and adolescents with DMD, we hypothesize that these
clinical characteristics are also directly associated with physical activity level and
functional ability related to activities of daily living. In turn, physical activity level and
functional ability may be associated with fatigue in DMD, as has been reported in adult
neuromuscular disorders [57,116]. Lastly, depression is the most commonly cited
neuropsychiatric disturbance to be associated with fatigue across chronic health conditions
[12,44,47,98], and may be associated with fatigue in boys with DMD.

Figure 1.2. A hypothesized model of fatigue in children and adolescents with Duchenne
muscular dystrophy.
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1.5

Objectives
With the exception of the past finding by our group of an association between

fatigue and poor health-related quality of life in children and adolescents with DMD [3],
data on fatigue and factors associated with fatigue in this population are lacking. To
facilitate the development of the best clinical practices to treat fatigue in children and
adolescents with DMD, an understanding of fatigue from both patients’ and parents’
perspectives, as well as potential factors contributing to fatigue in this population is needed.
The perspective of parents is important because it is typically the parents’ perceptions of
their child’s health status that influences healthcare utilization—particularly when the child
is too young, too cognitively impaired or too ill [117,118]. Therefore, the objectives of this
thesis are:
1. To describe subjective fatigue in a multicentre cross-sectional sample of
children and adolescents with DMD from patients’ and parents’ perspectives.
2. To explore associations of patient characteristics with child self-report and
parent proxy-report measures of subjective fatigue in a multicentre crosssectional sample of children and adolescents with DMD.
Hypothesis: Sleep disturbance symptoms, depressive symptoms, physical
activity level, functional ability related to activities of daily living,
musculoskeletal characteristics (ambulatory status, wheelchair use and
scoliosis), respiratory characteristics (forced vital capacity, NIV status) and
cardiac characteristics (left ventricular ejection fraction and cardiomyopathy
status) are associated with fatigue.
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Chapter 2
2
2.1

Literature Review
Background
While fatigue has been established as a complaint in adult neurologic and

neuromuscular disorders, the role of fatigue in paediatric neuromuscular disorders is not
yet well defined or studied [4,14,17,19,119]. Moreover, data regarding the role of fatigue
in Duchenne muscular dystrophy (DMD) are largely insufficient and lacking in both
paediatric and adult populations [3,120]. The aim of this literature review was to
summarize the current body of scientific literature relating to subjective fatigue in DMD,
as well as diseases with similar clinical manifestations, particularly other muscular
dystrophies and spinal muscular atrophy (SMA).
Other muscular dystrophies of interest were Becker muscular dystrophy (BMD),
Emery-Dreifuss muscular dystrophy (EDMD), limb girdle muscular dystrophies (LGMDs)
and facioscapulohumeral dystrophy (FSHD). BMD is a dystrophinopathy characterized by
later-onset and milder progressive muscle weakness and degeneration than DMD [36].
EDMD is characterized by joint contractures and slowly progressive muscle weakness and
wasting in a humeroperoneal distribution that later extends to the scapular and pelvic girdle
muscles [121]. DMD, BMD and EDMD are part of a larger group of LGMDs characterized
by weakness and wasting of the scapular and pelvic girdle muscles [122]. FSHD is
characterized by slowly progressive weakness of the facial muscles and the stabilizers of
the scapula or the dorsiflexors of the foot [123]. In contrast to the myopathies, SMA is
characterized by muscle weakness and atrophy caused by degeneration of lower motor
neurons in the anterior horn of the spinal cord and brain stem nuclei. SMA is amongst the
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most common childhood neuromuscular disorders, following DMD, and is classified into
different phenotypes per age of onset, maximum motor milestone achieved, and life
expectancy. Type I SMA is the most severe phenotype with onset before 6 months of age,
and characterized by sitting with support only as the maximum motor milestone attained.
Types II and III SMA are intermediate phenotypes with onset between 6–18 months and
after 18 months of age, respectively. Type II and III SMA are characterized by independent
sitting when placed and independent ambulation, respectively, as the maximum motor
milestones attained. Type IV SMA is the mildest phenotype with adult onset and normal
motor milestone attainment [124].
2.2

Search Strategy and Search Results
A literature search was conducted to identify quantitative, qualitative and mixed-

methods studies relating to subjective mental and/or physical fatigue, evaluated using
unidimensional or multidimensional questionnaires, in paediatric and adult muscular
dystrophies and spinal muscular atrophy. Studies assessing the relationship between
physiological fatigue and subjective fatigue were also included. Studies that combined
other disease populations with muscular dystrophies or SMA were included, so long as
disease-type was controlled for in the analysis or subgroup analyses were conducted. Only
studies published in English were included. Records were not excluded based on country
or date of publication. Review articles, editorials, commentaries and case reports were
excluded. The literature search was conducted using MEDLINE (Ovid), EMBASE,
CINAHL and PsycINFO databases on October 22nd, 2016. A comprehensive search
strategy was developed with guidance from a research librarian using terminology related
to muscular dystrophies, SMA and fatigue. The search strategy employed database-specific
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terminology and syntax, which are presented in Appendix A (Table A.1). Appropriate
Boolean operators and database-specific limitations were used to optimize search results.
A generic search strategy is presented below:
1. Database-specific subject headings for ‘muscular dystrophies’ OR ‘spinal
muscular atrophy’
2. Keywords: muscular dystroph* OR dystrophinopath* OR Duchenne muscular
dystrophy OR Becker muscular dystrophy OR Emery Dreifuss muscular dystrophy
OR facioscapulohumeral muscular dystrophy OR limb girdle muscular dystrophy
OR spinal muscular atrophy OR spinal muscle atrophy
3. (1) OR (2)
4. Database-specific subject headings for ‘fatigue’
5. Keywords: fatigue OR fatigability OR tired*
6. (4) OR (5)
7. (3) AND (6)
A total of 1,016 records were retrieved from databases (404 from MEDLINE (Ovid),
356 from EMBASE, 47 from CINAHL and 209 from PsycINFO), and 1 additional record
was retrieved through personal communication with the author. Duplicate records were
removed and records were screened in three consecutive stages by title, abstract and fulltext. Of the 867 records remaining after duplicate records were removed, 50 records met
eligibility criteria for full-text review and 27 records were ultimately included in this
literature review [3,57,58,98,116,120,125–145]. Reference lists of included studies and
excluded non-original studies were searched to ensure no records were omitted from the
search strategy. A study selection flowchart is presented in Appendix B (Figure B.1).
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2.3

Characteristics of Included Studies
Three themes emerged from studies included in this literature review: (1) the

burden of fatigue, (2) risk factors associated with fatigue, and (3) the management of
fatigue in muscular dystrophies and SMA. Although the management of fatigue in
muscular dystrophies and SMA is beyond the scope of the objectives of this thesis, these
studies were included as data on the effectiveness of interventions to treat fatigue can
provide insight on risk factors associated with fatigue. Study characteristics and findings
are summarized in Table 2.1 and Table 2.2. Studies were published between the years 2005
and 2016, underscoring the relative infancy of the study of subjective fatigue in muscular
dystrophies and SMA. Studies were conducted in the Netherlands [57,116,120,128,131–
133,136,139,140,142,143], United States of America [98,129,137,141], Japan [138],
Denmark [135,145], Canada [3,144], Italy [58,130], France [126,127], and Turkey
[125,134]. The majority of studies evaluating the burden of fatigue and/or risk factors
associated

with

fatigue

used

a

hypotheses-generating,

cross-sectional

design

[3,57,98,128,129,131–133,136,138,140,145], with the exception of three studies that
prospectively followed patients for 12 to 18 months [58,116,144]. Studies assessing the
management of fatigue were composed of randomized controlled trials (RCTs)
[126,137,142,143], non-randomized trials [125,134], single-arm trials [127,135], and a
prospective cohort study [130].
Four studies focused on paediatric DMD patients [3,58,125,144] and one study
focused on adult DMD patients [120], while the remaining studies primarily included
adults with other muscular dystrophies or SMA. Although studies of adults with muscular
dystrophies and SMA may have limited generalizability to fatigue in paediatric DMD, they
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can offer preliminary guidance for this novel area of research, including the conceptual
framework of this thesis. Moreover, studies of fatigue in DMD populations did not examine
associations between potentially modifiable risk factors and fatigue, further justifying the
need to turn to the scientific literature for other neuromuscular disorders.
2.4

Definition of Fatigue
Fatigue was most often defined as “an overwhelming sense of tiredness, lack of

energy and feeling of exhaustion” [57,116,120,131–133,136,139,142,145]. Werlauff et al.
added that patients experience difficulties in initiating or sustaining activities mentally,
physically or both [145]. Kalkman et al. differentiated fatigue from muscle weakness and
muscle fatigability [133]. Schipper et al. defined fatigue as “a subjective, unpleasant
symptom which incorporates total body feeling ranging from tiredness to exhaustion,
creating an unrelenting overall condition which interferes with an individual’s ability to
function to their normal capacity” [140]. In contrast, de Groot et al. referred to fatigue as a
“physical complaint” [128], and Noto et al. defined fatigue as “activity-induced muscle
weakness and fatigability” [138]. Fourteen studies did not offer a definition of fatigue
[3,58,98,125–127,129,130,134,135,137,141,143,144].
The lack of a commonly accepted definition of fatigue has previously been
highlighted as a challenge in studying fatigue [16]. Different definitions of fatigue may
result in differences in the reported prevalence and impact of fatigue in neuromuscular
disorders [9,17]. In a clinical setting, both physicians and patients often discuss fatigue
without explicitly defining the term [16]. In practice, the definition of fatigue may overlap
with sleepiness, depression, or muscle weakness [4,16]. Additionally, children with
neuromuscular disorders may not spontaneously report fatigue as a symptom or have the
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ability to clearly articulate the chief complaint [4,146]. Thus, the lack of a commonly
accepted definition of fatigue in research may translate to under-diagnosis or treatment
plans with unsatisfactory outcomes in clinical practice [4,9]. Furthermore, studies have
defined fatigue using different terms, yet employed the same instruments to measure
fatigue, calling into question the appropriateness and construct validity of these instruments
[120,138].
2.5

The Burden of Fatigue in Muscular Dystrophies and Spinal Muscular Atrophy
Studies included in this literature review demonstrated that fatigue was prevalent,

with far-reaching consequences on health-related quality of life (HRQOL) and patient
functioning in patients with muscular dystrophies and SMA. Studies characterizing the
burden of fatigue were limited to the patient populations of DMD, FSHD and SMA (Table
2.1).
2.5.1

Duchenne Muscular Dystrophy
In a Dutch cross-sectional study of adults with DMD (N=80), Pangalila et al.

reported fatigue to be present in 40.5% (95% CI: 29.7, 51.3%) of patients, with 21.5%
attributable to intermediate fatigue and 19.0% attributable to severe fatigue [120]. Fatigue
was measured using the Dutch version of the Fatigue Severity Scale (FSS). The FSS is
composed of nine items, each measured on a 7-point Likert scale from 1 (no signs of
fatigue) to 7 (most disabling fatigue). The FSS score is the mean of all item scores.
Intermediate fatigue was defined as a minimum score of 4 and severe fatigue was defined
as a minimum score of 5 [120,147]. Severe fatigue was more frequent in adults with DMD
(19.0%), compared to Dutch healthy controls from published data (5.0%) [120,148]. In
adults with DMD, fatigue was concurrent with pain in 11.4% of patients, with affective
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disorders (anxiety and depression) in 1.3% of patients, and with both pain and affective
disorders in 22.8% of patients. Fatigue was more prevalent in adult DMD patients with
poor quality of life (QOL) than in patients with good QOL. In multivariate logistic
regression analysis, with dichotomized QOL (good/poor) outcomes, fatigue emerged as a
determinant of overall QOL (OR=2.89; 95% CI: 1.71, 4.87; P<0.001), as well as QOL
related to physical functioning (OR=6.77; 95% CI: 2.11, 21.75; P=0.001) and environment
(OR=1.95; 95% CI: 1.16, 3.28; P=0.01), but not psychological functioning or social
relationships [120].
In a prospective cohort study by our group of children with DMD (N=98), fatigue
at baseline was significantly associated with worse overall, physical and psychosocial
HRQOL at baseline, by child self-report and parent-proxy report [3]. Fatigue was measured
using the Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional Fatigue
Scale (MFS). The PedsQLTM MFS is an 18-item form composed of three domains: General
Fatigue (six items), Sleep/Rest Fatigue (six items) and Cognitive Fatigue (six items) [117].
HRQOL was also assessed using the PedsQLTM measurement model with generic and
disease-specific measures: Generic Core Scales, Neuromuscular Module and Duchenne
Muscular Dystrophy Module [149,150]. Of the patient and family characteristics examined
as independent variables in multivariable linear regression analysis, only fatigue was
associated with all measures of HRQOL at baseline (=0.38 to =0.88; P<0.001 to
P=0.02). Fatigue explained more of the variability in HRQOL than any other variable
examined, as determined by backward elimination regression analysis. Other variables
examined were age, wheelchair use, scoliosis, corticosteroid therapy, forced vital capacity,
left ventricular ejection fraction, diagnosis with one or more neuropsychiatric disorder,
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family stress, annual household income and parents’ highest educational attainment [2,3].
Patients were then followed for 18 months and the longitudinal relationship between
fatigue and HRQOL was examined in children with DMD (N=49). Change in fatigue was
significantly correlated with change in HRQOL over 18 months, by child self-report and
parent proxy-report (r=0.50 to r=0.81; P<0.001 to P=0.003) [144]. Because fatigue and
HRQOL were both assessed using the PedsQLTM measurement model, it is possible that
their association was an artifact due to common method variance—shared variance among
variables attributable to the measurement model rather than the constructs the measures
represent [151]. Common method variance can inflate or deflate observed relationships
between predictor and criterion variables, resulting in both Type I and Type II errors,
respectively [151,152].
In an Italian prospective cohort study, Messina et al. evaluated 12-month change in
fatigue, also using the PedsQLTM MFS by child self-report and parent proxy-report, in
ambulant children with DMD (N=98) [58]. At baseline and 12-months, children with DMD
experienced greater fatigue than healthy controls from published data by child self-report
and parent proxy-report [58,117,118]. No significant change in child self-reported fatigue
was observed over 12 months, however parent proxy-reported fatigue significantly
increased over 12 months (P=0.002) [58].
2.5.2

Other Muscular Dystrophies
Severe fatigue (Checklist Individual Strength Fatigue subscale score 35 [153])

was reported by 34–61% of adults with FSHD [57,142]. Adults with FSHD reported higher
levels of current fatigue than healthy controls [139,142]. In a cross-sectional survey of
FSHD patients, combined with myotonic dystrophy patients, fatigue was the most frequent
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and severe symptom reported by patients, relative to imbalance, pain, memory loss and
vision loss. Fatigue was most often reported to worsen or stay the same, rather than
improve, since its onset and over the course of the past six months [141]. In adults with
FSHD, fatigue has been reported to be associated with poor physical and psychological
functioning, greater depressive symptoms and functional impairment [98,116,141].
Functional impairment was measured using the following subscales from the Sickness
Impact Profile: body care and movement, home management, communication, work
limitations, recreation and pastimes, and impairments with eating [116,154]. Despite a high
prevalence of severe fatigue among FSHD patients, severe fatigue was not associated with
employment status. Thus, fatigue can impair patient functioning, but is not related to
participation in the workforce. However, types of occupations and number of hours worked
have not been explored in this population [136]. In a qualitative study of fatigue in adults
with FSHD using semi-structured interviews [140], respondents described fatigue as an
overwhelming, unpredictable and capricious experience with physical and psychological
components. The psychological component was described as a fear of becoming fatigued,
which resulted in reluctance to participate in activities. Respondents indicated that fatigue
negatively influenced activities of daily living, social participation and participation in
work [140].
2.5.3

Spinal Muscular Atrophy
Data regarding the burden of fatigue in SMA are sparse, inconclusive and limited

to cross-section studies. Patient populations varied across studies with respect to SMA
phenotype, limiting comparability of findings [128,129,138,145]. In a study of SMA and
spinal and bulbar muscular atrophy (SBMA) patients, adults with SMA (unspecified type)
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or SMBA reported significantly greater fatigue than healthy controls [138]. In a study by
de Groot et al., fatigue was significantly more prevalent in Type III SMA patients (61%)
than in Types I and II SMA patients (34%). Moreover, fatigue was one of the most
frequently reported physical complaints among Type III SMA patients, preceded only by
muscle weakness and cold hands or feet [128]. In a study of adults with Type II SMA,
severe fatigue was reported by only 10% of patients, corroborating the finding by de Groot
et al. that fatigue may not be a common feature in Type II SMA [128,145]. Data regarding
the burden of fatigue in children with SMA were limited to a published abstract [129].
Fatigue was assessed in children with Type II or III SMA using the PedsQLTM MFS.
Children with SMA reported greater fatigue than healthy controls from published data
[117,118,129]. However, fatigue was not associated with quality of life or function in Type
II or III SMA patients [129].
2.6

Factors Associated with Fatigue in Muscular Dystrophies and Spinal Muscular
Atrophy

2.6.1

Duchenne Muscular Dystrophy
In the prospective cohort study conducted by our group, children with DMD using

a wheelchair intermittently reported significantly greater fatigue than children not using a
wheelchair, indicating that the transition into wheelchair use may be associated with
fatigue. This association was not present by parent proxy-report [3]. Messina et al. assessed
whether 12-month change in functional ability was associated with 12-month change in
fatigue in ambulant children with DMD [58]. Functional ability was assessed using
measures commonly used in therapeutic trials and clinical practice, including the sixminute walk test (6MWT), North Start Ambulatory Assessment (NSAA), 10-metre
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walk/run test, and time to rise from the floor (Gowers’ test) [155–157]. The NSAA is a 17item scale that assesses abilities necessary to remain functionally ambulant in children with
DMD [157]. Few associations between functional ability and fatigue were observed by
Messina et al., suggesting that functional ability, a proxy for disease severity in DMD, may
be weakly related to fatigue. At baseline, shorter 6MWT distance was weakly associated
with greater fatigue, by child self-report (r=0.23; P=0.02) and parent proxy-report (r=0.27;
P=0.006). Greater time to rise from the floor was weakly associated with greater fatigue,
by child self-report (r=-0.21; P=0.04). Over 12 months, change in 10-metre walk test was
weakly associated with change in fatigue, by child self-report (r=-0.22; P=0.03). Because
a significant 12-month decline in functional ability was observed in children >7 years of
age, a subgroup analysis was conducted for this age group. In children >7 years of age, 12month change in 6MWT was weakly associated with change in fatigue, by child self-report
(r=0.24; P=0.01) and parent proxy-report (r=0.25; P=0.03). NSAA and age were not
associated with fatigue in ambulant children with DMD [58]. However, the correlation
analyses using cross-sectional data by our group [3] and Messina et al. [58] do not allow
for causal conclusions regarding the relationship of physical functioning with fatigue in
children with DMD. No additional studies have explored factors associated with fatigue in
children with DMD.
2.6.2

Other Muscular Dystrophies
Eight studies conducted in the Netherlands examined factors associated with

fatigue in adults with FSHD [57,116,131–133,139,140,142]. All studies, except one [140],
recruited patients from the Neuromuscular Centre at Radboud University Nijmegen
Medical Centre and the Dutch Neuromuscular Diseases Association (Vereniging
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Spierziekten Nederland). A common patient source across studies may limit the
generalizability of findings [57,116,131–133,139,142]. Using a prospective cohort study
design and structural equation modelling, Kalkman et al. aimed to identify predictors of
fatigue and to develop a model of fatigue in adults with FSHD. Model testing revealed that
sleep disturbances, pain, physical activity level and muscle strength were significantly
associated with fatigue. Sleep disturbances, pain and physical activity level had a direct
causal effect on fatigue, while muscle strength had an indirect effect on fatigue mediated
by physical activity level [116]. The associations of pain and physical activity level (overexertion or excessive rest) with fatigue reported by Kalkman et al. [116] corroborate
previous findings [57,140,142]. However, van der Kooi et al. did not observe a difference
in physical activity level between FSHD patients with and without severe fatigue [142].
Kalkman et al. did not observe an association between neuropsychological functioning
(concentration, alertness, information-processing speed and motor speed) and fatigue
[116]. However, it was previously reported that severely fatigued patients have more
concentration problems and reduced motivation compared with less fatigued patients [57].
Data regarding the relationship between mental health and fatigue in FSHD are
inconclusive. No difference in fatigue severity was observed between FSHD patients with
and without current or lifetime psychiatric disorders evaluated using the Structured
Clinical Interview for DSM-IV Axis I Disorders [131,158]. Self-reported mental health
and depressive symptoms have been statistically analyzed as both determinants and
outcomes of fatigue. Reports of significant associations of mental health and depressive
symptoms with fatigue are inconsistent across studies [57,98,116,131,141,142]. Thus, the
strength and directionality of associations of mental health and depressive symptoms with
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fatigue in FSHD remain unclear. Similarly, physical functioning has been statistically
analyzed as both a determinant and an outcome of fatigue in FSHD, and has consistently
been reported to be associated with fatigue [57,98,142]. Kalkman et al. did not observe an
association between social functioning or social support and fatigue [116]. However, a
study assessing the influence of relatives on fatigue experienced by FSHD patients
demonstrated that receiving higher levels of sympathetic or empathic support from
relatives was associated with greater fatigue experienced by patients. Moreover, fatigue
severity experienced by relatives was significantly associated with fatigue severity
experienced by patients [132]. Age and sex were not associated with fatigue in FSHD
[57,142]. In a qualitative study by Schipper et al. [140], coping and stress were identified
as risk factors for fatigue in FSHD. Semi-structured interviews with adults with FSHD
ultimately demonstrated that the source of fatigue may be a complex network of factors.
However, patients are often unaware of the causes of fatigue, making it difficult to manage
[140].
The relationship between physiological fatigue and subjective fatigue in FSHD has
been examined by two studies [133,139]. Physiological fatigue—the inability to maintain
the desired muscle force during sustained or repeated exercise—can originate at the level
of the central nervous system (upper motor neuron) or peripheral nervous system (lower
motor neuron, neuromuscular junction or muscle) [16]. Peripheral and central aspects of
physiological fatigue are measured in a laboratory setting using electrophysiological
protocols such as intermittent submaximal exercise protocol, sustained maximal force
exercise protocol, twitch interpolation or transcranial magnetic stimulation [16,159]. Using
a twitch interpolation technique [159], Schillings et al. [139] and Kalkman et al. [133]
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demonstrated that total physiological fatigue, peripheral physiological fatigue, and central
physiological fatigue were not correlated with subjective fatigue measures in adults with
FSHD. This finding suggests that physiological and subjective fatigue are separate types
of fatigue. The mechanisms and determinants of physiological and subjective fatigue may
differ, requiring targeted interventions [133].
2.6.3

Spinal Muscular Atrophy
Two studies examined factors associated with fatigue in SMA and did not observe

any significant associations [129,138]. Age, SMA phenotype, ambulatory status, disease
duration and degree of disability were not associated with fatigue [129,138]. Physiological
fatigue, determined by the decrement in distance from the first to sixth minute during the
6MWT [155], was not associated with subjective fatigue in ambulant Type II or II SMA
patients [129]. Physiological fatigue, determined by activity-dependent conduction blocks
during simulated-single fibre electromyography [160], was not associated with subjective
fatigue in SMA (unspecified type) or SBMA patients [138].
2.7

The Management of Fatigue in Muscular Dystrophies and Spinal Muscular
Atrophy

2.7.1

Duchenne muscular dystrophy
In a non-randomized trial, Alemdaroğlu et al. [125] aimed to assess the acute

effects of various exercise protocols on fatigue in ambulant children with DMD (N=30).
Patients were assigned to one of the following exercise protocols per session: (1) 3 minutes
of 5-step stair-climbing, (2) 40 minutes of stationary cycling, or (3) a 40-minute physical
therapy program of stretching the gastrocnemius, hamstring and hip flexor muscles,
strengthening upper and lower extremities and aerobic activity. Fatigue was evaluated on
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the same day following each exercise protocol using the Pictorial Variant of the Children’s
Effect Rating Scale Table scale—an illustrated visual analog scale of 0–10 with a presentstate recall period [161]. Telephone-interviews were conducted the second day following
exercise protocols to evaluate whether post-exercise fatigue affected patients’ activities of
daily living. A significant increase in fatigue was reported immediately following each
exercise protocol compared to baseline, however post-exercise fatigue did not influence
activities of daily living on the same day of exercise [125]. No studies have evaluated the
effects of exercise therapy or other interventions on long-term fatigue in paediatric or adult
DMD.
2.7.2

Other Muscular Dystrophies
The effects of exercise therapy, neuromuscular electrical stimulation therapy,

pharmacological therapy with salbutamol, and cognitive behaviour therapy (CBT) on
fatigue have been assessed in adults with FSHD or LGMD [126,127,134,142,143]. No
significant changes in fatigue were observed following 8–26 weeks of exercise therapy
consisting of strength training only in FSHD or LGMD patients [134,142]. However, a
significant reduction in fatigue was observed following 16–24 weeks of aerobic exercise
therapy alone or in combination with strength training [126,143]. A decrease in subjective
fatigue, following combined aerobic and strength training, was associated with a decrease
in physiological fatigue and an improvement in mental health [126]. Neuromuscular
electrical stimulation therapy is a passive muscular training technique used to prevent
muscular atrophy, which demonstrated safety and efficacy in stabilizing or improving
muscular weakness in DMD patients [162–166]. Although no significant changes in fatigue
were observed following neuromuscular electrical stimulation therapy in FSHD and
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LGMD patients, an improvement in the impact of fatigue on activities of daily living was
reported by FSHD patients [127,134]. The 2-adrenergic receptor agonist salbutamol has
previously been reported to increase muscle mass and strength in FSHD patients, however
the anabolic effect diminished with prolonged use [167,168]. No significant changes in
fatigue were observed following 26 weeks of therapy with salbutamol alone or in
combination with strength training [142].
In contrast to therapies that target physical components of fatigue, CBT facilitates
the identification of maladaptive thoughts, beliefs and attitudes. CBT challenges these
cognitions through collaborative hypothesis-testing, using behavioural tasks of diarykeeping and validity-testing of beliefs between sessions, combined with the development
of coping strategies within sessions [169]. Studies have demonstrated that CBT can reduce
fatigue in patients with chronic fatigue syndrome and multiple sclerosis [169,170]. In an
evaluator-blind RCT by Voet et al. [143], CBT significantly reduced fatigue severity in
adults with FSHD compared to usual care. CBT and aerobic exercise therapy produced
quantitatively similar beneficial effects on fatigue. However, CBT improved all fatigueperpetuating factors, except pain, in the model described by Kalkman et al. [116], whereas
physical activity level was the only fatigue-perpetuating factor modified by aerobic
exercise therapy [143]
2.7.3

Spinal Muscular Atrophy
The effects of exercise therapy and pharmacological therapy with salbutamol on

fatigue have been assessed in SMA. Following 12–24 weeks of aerobic exercise therapy
(stationary cycling) alone or in combination with strength training, Type III SMA patients
reported no change in fatigue or worsened fatigue [135,137]. In contrast, training-induced
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fatigue was not observed in studies evaluating aerobic exercise therapy in muscular
dystrophies [126,143], suggesting alternative underlying mechanisms of fatigue in
muscular dystrophies and anterior horn cell disease, which may require disease-specific
therapies [135].
SMA is caused by a deficit of survival motor neuron (SMN) protein encoded by the
SMN1 and SMN2 genes. Patients have homozygous pathogenic variants of the SMN1 gene
and retain at least one copy of the SMN2 gene. However, the SMN2 gene produces
insufficient levels of functional protein due to the exclusion of exon 7 in most transcripts
caused by alternative splicing [171]. Studies have demonstrated that treatment with the 2adrenergic receptor agonist salbutamol increase expression of full-length SMN2
transcripts, and may increase motor function in SMA patients [172–175]. Giovannetti et
al. assessed the perceived effects of salbutamol on fatigue in adults with Type II, III or IV
SMA. A significant reduction in fatigue was reported by patients following treatment with
salbutamol [130].
2.8

Conclusions
This literature review highlights the need for additional studies to characterize the

prevalence of and factors associated with fatigue in children and adolescents with DMD.
Understanding the determinants of fatigue in paediatric DMD is necessary for the
development of treatment strategies that produce positive clinical outcomes. This review
demonstrated fatigue to be frequent and disabling in patients with DMD, FSHD and SMA,
and likely caused by multiple, dynamic factors. Much of the data presented in this review
focused on adults with slowly progressive forms of muscular dystrophies or mild
phenotypes of SMA. The clinical presentations of FSHD, LGMD, and Type III and IV
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SMA are uncharacteristic of DMD. Although findings presented in this literature review
are hypothesis-generating for this thesis, they may be unrelated to phenomena in children
or adults with DMD. Contrasting results across patient populations, with respect to
determinants of and therapeutic interventions for fatigue, further underscore the role of
disease-specific mechanisms of fatigue. Data regarding the management of fatigue in both
children and adults with muscular dystrophies and SMA are largely insufficient. However,
the assessment of therapeutic interventions to modify fatigue is ultimately dependent on
understanding disease-specific mechanisms of fatigue in these patient populations.
Prospective cohort studies with larger, representative sample sizes are needed to
characterize fatigue in both paediatric and adult muscular dystrophies and SMA. However,
an initial cross-sectional study of factors associated with fatigue in paediatric DMD can
inform the design of future longitudinal studies.
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Table 2.1. Studies on the frequency of and factors associated with fatigue in muscular dystrophies and spinal muscular atrophy
Author, Year,
Country
[publication]

Study Design
(Follow-up)

Disease
(Sample Size)
Patient Source(s)
DMD (80)

Pangalila,
2015,
Netherlands
[120]

Crosssectional
study

Wei, 2015,
Canada [144]a

Prospective
cohort study
(18 months)

DMD (49)

Crosssectional
study

DMD (98)

Prospective
cohort study
(12 months)

DMD (98)

Wei, 2016,
Canada [3]

Messina,
2016, Italy
[58]

Age in
Years
Mean  SD
(Range)
28.2  6.3
(20–44)

Subjective Fatigue
Assessment
FSS (recall-period not
reported)

Fatigue present in 40.5% of adult DMD patients. Univariate
logistic regression analysis demonstrated fatigue
significantly associated with poor overall QOL and domains
of physical health, psychological functioning and
environment, but not social relationships. Multivariate
logistic regression analysis demonstrated fatigue
significantly associated with poor overall QOL and domains
of physical health and environment.

12.2 (5–19)

PedsQLTM MFS,
patient- and parent
proxy-report (4-week
recall period)

Change in fatigue significantly correlated with changes in
child self- and parent proxy-reported HRQOL over 18
months.

10.7  3.7

PedsQLTM MFS,
patient- and parent
proxy-report (4-week
recall period)

Multivariable linear regression analysis revealed fatigue
significantly associated with child self- and parent proxyreported overall, physical and psychosocial HRQOL.
Fatigue explained more variability in HRQOL than any
other patient or family characteristic.

8.4  2.29

PedsQLTM MFS,
patient- and parent
proxy-report

Included DMD patients were ambulant. Parent proxy-, but
not child self-reported, fatigue significantly increased over
12 months. Baseline child self-reported fatigue significantly
correlated with time to rise from floor and 6MWT. Baseline
parent proxy-reported fatigue significantly correlated with
6MWT. 12-month change in patient-reported fatigue
significantly correlated with change in 10-meter timed
walk/run test. In children 7 years of age, 12-month change
in child self- and parent proxy-reported fatigue significantly
correlated with change in 6MWT.

Four Centres for Home
Ventilation in the Netherlands;
Dutch rehabilitation centres;
Dutch patient organization for
neuromuscular diseases

Canadian Neuromuscular Disease
Registry

Canadian Neuromuscular Disease
Registry

Ten tertiary neuromuscular
centres in Italy

Summary of Findings
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Author, Year,
Country
[publication]

Study Design
(Follow-up)

Disease
(Sample Size)
Patient Source(s)
FSHD (65)

Kalkman,
2007,
Netherlands
[131]

Crosssectional
study

Schillings,
2007,
Netherlands
[139]

CrossSectional
study

FSHD (65)

Kalkman,
2007,
Netherlands
[116]

Prospective
Cohort Study
(18 months)

FSHD (60)

Age in
Years
Mean  SD
(Range)
43.1  10.3

Subjective Fatigue
Assessment

Summary of Findings

CIS-Fatigue (2-week
recall period)

Current and lifetime psychiatric disorders not associated
with fatigue.

43.1  10.3
(22.5–60.9)

SFQ (Present-state
recall period)

Patients reported greater subjective fatigue than healthy
controls. Total, peripheral and central physiological fatigue
not correlated with subjective fatigue. FSHD patients
experienced greater central activation failure than controls;
central activation failure not significantly correlated with
subjective fatigue.

44.3  9.9

CIS-Fatigue (2-week
recall period)

Physical activity, depressive symptoms, sleep disturbances,
pain and muscle strength correlated with fatigue.
Neuropsychological impairment, social functioning and
social support not correlated with fatigue.

Neuromuscular Centre, Radboud
University Nijmegen Medical
Centre; Dutch patient organization
for neuromuscular diseases

Neuromuscular Centre, Radboud
University Nijmegen Medical
Centre; Dutch patient organization
for neuromuscular diseases

Neuromuscular Centre, Radboud
University Nijmegen Medical
Centre; Dutch patient organization
for neuromuscular diseases

Kalkman,
2008,
Netherlands
[133]

Crosssectional
study

FSHD (65)

Minis, 2010,
Netherlands
[136]

Crosssectional
study

FSHD (138)

Structural equation modelling demonstrated sleep
disturbances at baseline had direct effect on fatigue at
follow-up. Pain at baseline had direct effect on physical
activity at baseline and fatigue at follow-up. Muscle strength
at baseline had indirect effect on fatigue at follow-up via
physical activity at baseline. Fatigue at follow-up has direct
effect on functional impairment at follow-up.
43.1  10.3

CIS-Fatigue (2-week
recall period)

Peripheral and central physiological fatigue did not correlate
with subjective fatigue, suggesting that these are separate
types of fatigue.

43.7  10.1

CIS-Fatigue (2-week
recall period)

Bivariate analysis demonstrated employed patients reported
significantly less fatigue than unemployed patients.

Neuromuscular Centre, Radboud
University Nijmegen Medical
Centre; Dutch patient organization
for neuromuscular diseases
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Author, Year,
Country
[publication]

Study Design
(Follow-up)

Disease
(Sample Size)
Patient Source(s)
Neuromuscular Centre, Radboud
University Nijmegen Medical
Centre; Dutch patient organization
for neuromuscular diseases

Alschuler,
2012, USA
[98]

Crosssectional
study

FSHD (139)

Noto, 2013,
Japan [138]

Crosssectional
study

SMA (5)
SBMA (17)

Age in
Years
Mean  SD
(Range)

Subjective Fatigue
Assessment

However, multivariate regression analysis demonstrated
fatigue not associated with employment status.

53.6  13.8
(22–89)

NRS of 0–10 with a 1week recall period

Hierarchal linear regression analyses demonstrated greater
fatigue significantly associated with poor physical
functioning and greater depressive symptoms, independent
of pain and age. Fatigue explained more variability in
depressive symptoms than physical functioning.

59 (37–75)

FSS (recall-period not
reported)

SMA/SBMA patients reported significantly greater fatigue
than healthy controls and other patient populations (multiple
sclerosis, myasthenia gravis, chronic inflammatory
demyelinating polyneuropathy and axonal neuropathy),
although differences not significant. Fatigue not correlated
with age, disease duration, degree of disability or
conduction blocks during stimulated-single fibre EMG.

30.6  10.5
(19–55)

FSS (2-week recall
period)

Three patients (10%) patients reported severe fatigue,
indicating fatigue may not be common in SMA II. Fatigue
not associated with age or sex.

(5–49)

PedsQLTM MFS; FSS
(recall periods not
reported)

All patients reported subjective fatigue. Fatigue not
associated with age, SMA type, ambulatory status, function
or QOL in all patients, or with physiological fatigue in
ambulatory patients.

51.9  13.1
(21–90)a

NRS of 0–10
(severity); patients
asked to indicate
whether fatigue had
become worse, become

Fatigue was the most common and severe symptom, relative
to imbalance, pain, memory impairment and vison loss.
Fatigue most often worsened or stayed the same since onset
and during past 6 months. Bivariate analysis demonstrated
fatigue significantly correlated with psychological

Previous study participants;
Individuals responding to
advertisements through Muscular
Dystrophy Foundation,
publications and clinics

Chiba University Hospital

Werlauff,
2014,
Denmark
[145]

Mixed
methods
crosssectional
study

SMA II (29)

Dunaway,
2014, USA
[129]a

Crosssectional
study

SMA II (7);
SMA III (25)

Danish National Rehabilitation
Center for Neuromuscular
Diseases

Smith, 2014,
USA [141]

Crosssectional
study

FSHD (90)
National Registry of DM and
FSHD; University of Washington
Muscular Dystrophy Association

Summary of Findings
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Author, Year,
Country
[publication]

Schipper,
2016,
Netherlands
[140]

Study Design
(Follow-up)

Disease
(Sample Size)
Patient Source(s)
clinic roster; Previous study
participants; Individuals
independently contacting
researchers

FSHD (25)

53.8  12.4
(24–77)

Subjective Fatigue
Assessment

Summary of Findings

better or stayed the
same since its onset,
and during the past 6
months (symptom
course)

functioning, social integration, home competency and
productive activity. When controlling for other symptoms,
age, sex and disease duration, multivariable linear
regression analyses revealed fatigue only significantly
associated with psychological functioning.b

Four themes identified: (1) fatigue is overwhelming and
unpredictable with physical and mental component; (2)
Previous study participants;
fatigue caused by combination of factors (weak muscles,
Computer Registry of All
physical overachieving or underachieving, stress). Causes
Myopathies and
unknown most of time, making fatigue difficult to deal with;
Polyneuropathies; patient support
(3) fatigue influences participation, social contacts and
organizations
activities of daily of living; (4) managing fatigue requires
adaption to changing situations of progressive disease,
making it more difficult.
Abbreviations: DMD, Duchenne muscular dystrophy; QOL, quality of life; HRQOL, health-related quality of life; 6MWT, six-minute walk test; FSS, Fatigue Severity Scale;
PedsQLTM MFS, Pediatric Quality of Life InventoryTM Multidimensional Fatigue Scale; FSHD, facioscapulohumeral dystrophy; CIS-Fatigue, Checklist Individual Strength
Fatigue subscale; SFQ, Shortened Fatigue Questionnaire; NRS, numerical rating scale; SMA, spinal muscular atrophy; SBMA, spinal and bulbar muscular atrophy; VAS, visual
analog scale.
aMeeting

Qualitative
CrossSectional
study

Age in
Years
Mean  SD
(Range)

Semi-structured
interviews [Patients
previously reported
severe fatigue (CISFatigue scores 35)]

abstract
analysis combined FSHD and myotonic dystrophy type 1 patients, however dystrophy type did not moderate associations between fatigue and criterion variables.

bStatistical
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Table 2.2. Studies on the management of fatigue in muscular dystrophies and spinal muscular atrophy
Disease
(Sample Size)

Author, Year,
Country
[publication]

Study Design (Followup)

Alemdaroğlu,
2012, Turkey
[125]

Open-label, nonrandomized trial (1 day)

van der Kooi,
2007,
Netherlands
[142]

Evaluator-blind RCT of
training/non-training,
followed by doubleblind RCT of
salbutamol/placebo (52
weeks)

Strength training of
elbow flexors and
ankle dorsiflexes or
non-training (26
weeks), followed by
salbutamol (sustainedrelease 8 mg BID) or
placebo (26 weeks)

FSHD (65)

Colson, 2010,
France [127]

Single-arm trial (5
months)

5-month strength
training with
neuromuscular
electrical stimulation
(5 20-minute sessions
weekly)

FSHD (9)

Intervention(s)
3-minute stair
climbing; 40-minute
cycling; 40-minute
stretchingstrengthening with
aerobic exercises for
extremities

Patient Source(s)
DMD (30)

Age in Years
Mean  SD
(Range)

Subjective Fatigue
Assessment

Summary of Findings

7.87  1.45
(6–11)

Pictorial Variant of
the Children’s
Effort Rating Scale
(VAS of 0–10;
present state recall
period)

Significant increase in fatigue
observed immediately following
exercise compared to baseline.
Post-exercise fatigue did not affect
performance of daily activities on
same day of exercise.

38  10

CIS-Fatigue (2week recall period)

Twenty-two patients (34%) had
severe fatigue at baseline. Patients
reported greater fatigue compared
to healthy controls from published
data. Severely fatigued patients
experienced significantly more
pain, functional disability,
psychological distress and
depressive feelings. Age, sex and
self-reported daily activity not
associated with severe fatigue.
Strength training and salbutamol,
alone or in combination, did not
affect fatigue.

55.2 (39–69)

VAS of 0–10
(present state recall
period); Patients
rated changes in
fatigue related to
daily living as
worse, unchanged
or improved at the
end of the study
period

No significant change in fatigue
observed following training with
electrical stimulation. Seven
patients (78%) reported improved
fatigue related to daily living.

Physical Therapy
Department, Hacettepe
University

Neuromuscular Centre,
Radboud University
Nijmegen Medical
Centre; Dutch patient
organization for
neuromuscular diseases

Neuromuscular Disease
Centre of Nice, France
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Author, Year,
Country
[publication]

Study Design (Followup)

Voet, 2014,
Netherlands
[143]

Evaluator-blind RCT
(28 weeks)

Madsen, 2015,
Denmark
[135]

Single-arm trial (12
weeks)

Montes, 2015,
USA [137]

Evaluator-blind RCT (6
months)

Kilinç, 2015,
Turkey [134]

Open-label, nonrandomized trial (8
weeks)

Intervention(s)
Aerobic exercise
training (38-minute
cycling 3 times
weekly for 16 weeks);
CBT (minimum 3 50minute sessions over
16 weeks); usual care

Disease
(Sample Size)
Patient Source(s)
FSHD I (57)

Age in Years
Mean  SD
(Range)

Subjective Fatigue
Assessment

(20–79)

CIS-Fatigue (2week recall period)

All patients severely fatigued.
Fatigue significantly reduced
following 16 weeks of aerobic
exercise or CBT compared to usual
care. Beneficial effects remained at
12-week follow-up without
supervised treatment. Posttreatment, 76% in CBT group and
50% in the aerobic exercise group
no longer severely fatigued.
Aerobic exercise and CBT
produced similar effects on fatigue,
despite fewer CBT sessions.

32.5  16.49

Patients rated
changes in fatigue
as worse,
unchanged or
improved at the end
of the study period

All patients reported worsened or
no change in fatigue following
training. One patient dropped out
due to excessive fatigue.

27.0  14.6
(10–43;
exercise); 26.7
 17.7 (10–
48; control)

PedsQLTM MFS;
FSS (recall periods
not reported)

No significant changes in fatigue,
between or within, the exercise and
control groups were observed.

31.62  16.92
(electrical
stimulation);
30.14  11.04
(exercise
therapy)

VAS of 0–10
(present state recall
period)

Fatigue did not increase after
electrical stimulation applications
or exercise therapy.

Previous study
participants; Dutch
neuromuscular database,
Computer Registry of
All Myopathies and
Polyneuropathies;
patient support
organizations

Home-based aerobic
exercise training (30minute cycling 2–4
times weekly, totaling
42 sessions)

SMA III (6)

Home-based exercise
training (30-minute
cycling 5 times
weekly, 30-minute
strength training 3
times weekly); usual
care (control)

SMA III (12)

Electrical stimulation
(high voltage pulsed
galvanic stimulation 3
days weekly); exercise
therapy (moderate
intensity progressive

LGMD (24)

-

SMA Clinical Research
Center, Columbia
University Medical
Center; Pediatric
Neuromuscular Clinical
Research Network;
ClinicalTrials.gov

Physical Therapy
Department, Hacettepe
University

Summary of Findings
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Author, Year,
Country
[publication]

Study Design (Followup)

Intervention(s)

Disease
(Sample Size)
Patient Source(s)

Age in Years
Mean  SD
(Range)

Subjective Fatigue
Assessment

Summary of Findings

resistance exercises 3
days weekly)
Bankolé,
2016, France
[126]

Open-label RCT (24
weeks), followed by
single-arm trial for
patients initially
assigned to control
group (24 weeks)

Home-based exercise
training (35-minute
cycling 3 times
weekly); usual care
(control)

FSHD (16)

40  13
(training);
41  9
(control)

FSS (recall period
not reported)

Subjective Fatigue significantly
decreased over 24-weeks in patients
Centre Hospitalier
in exercise group compared to
Universitaire de Saintcontrols. Decreased subjective
Etienne; entre
fatigue significantly correlated with
Hospitalier Universitaire
decreased physiological fatigue
de Grenoble
(increases in VO2 max, MAP,
MVC, muscle endurance and
6MWT) and improved mental
health.
Giovannetti,
Mixed methods;
Salbutamol
SMA II (1)
FSS (recall period
Patients treated with salbutamol for
41.3  11.2
2016, Italy
Prospective cohort
SMA III (6)
not reported); Semi- 30  20.2 months before study. At
[130]
study (1 year)
SMA IV (3)
structured
initial evaluation, patients reported
interviews
significantly less fatigue after
salbutamol treatment. One year
after initial evaluation, patients
reported stability of fatigue, not
improvement.
Abbreviations: DMD, Duchenne muscular dystrophy; VAS, visual analog scale; RCT, randomized controlled trial; FSHD, facioscapulohumeral dystrophy; CIS-Fatigue,
Checklist Individual Strength Fatigue subscale; CBT, cognitive behavioural therapy; SMA, spinal muscular atrophy; PedsQLTM MFS, Pediatric Quality of Life InventoryTM
Multidimensional Fatigue Scale; LGMD, limb girdle muscular dystrophies; VO2 max, maximal oxygen consumption; MAP, maximal aerobic power; MVC, isometric maximal
voluntary contractions; 6MWT, six-minute walk test; FSS, Fatigue Severity Scale.
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Chapter 3
3

Methods

3.1

Study Design
The study described in this thesis is a cross-sectional survey study of children and

adolescents with Duchenne muscular dystrophy (DMD) identified via the Canadian
Neuromuscular Disease Registry (CNDR). Eligible patients, and their parent or primary
caregiver, were sent paper questionnaires by mail between July 2016 and November 2016.
Approval of the study was obtained from the Health Sciences Research Ethics Board at
The University of Western Ontario (Western University) and the CNDR Advisory
Committee. Approval Notices from the Health Sciences Research Ethics Board at Western
University are presented in Appendix C.
3.2
3.2.1

Study Population
Patient Source
Eligible patients were recruited through the CNDR. The CNDR is a multicentre

clinic-based registry that was established in June 2011 to facilitate national and
international research opportunities between researchers and patients, and clinical
knowledge translation to allow for uniform standards of care across Canada. Paediatric and
adult patients with any neuromuscular disorder who are residents in Canada are eligible for
enrollment in the CNDR. The CNDR is administered and supported centrally at the
National Office at the University of Calgary in Alberta, Canada. The CNDR employs a
blended recruitment model in which patients are actively recruited at participating
neuromuscular clinics in combination with self-registration by contacting the CNDR
National Office for patients unable to attend affiliated neuromuscular clinics. Any

46
physician in Canada can refer a patient to the CNDR for enrollment, by completing
registration forms available via the National Office or guiding patients to self-register. This
recruitment model provides access to patients across Canada, including those in remote
regions with limited access to specialized neuromuscular care. The CNDR includes
patients recruited from nine paediatric neuromuscular clinics across Canada located in
British Columbia, Alberta, Ontario, Quebec and Nova Scotia. Clinics enroll patients and
collect medical and demographic information at routine clinic visits. Each neuromuscular
clinic is affiliated with an academic institution and has a site principal investigator (Table
D.1, Appendix D). All patients provide voluntary, informed consent for enrollment,
updating of demographic and medical information at future routine clinic visits, and
notification of research studies for which they may be eligible. Patients who are minors can
be registered by a parent or legal guardian, and are asked to provide assent when possible.
Upon reaching the age of majority in their province of residence, patients are asked for
their consent to remain in the registry [176].
3.2.2

Patient Inclusion and Exclusion Criteria
Patients were identified by the CNDR National Office staff for inclusion in the

study reported here according to the following inclusion and exclusion criteria:
Inclusion Criteria
1. Patients are enrolled in the CNDR. To be enrolled in the CNDR, subjects must:
a. Consent to have clinical information submitted by a physician licensed and
practicing in Canada.
b. Be residents in Canada.
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2. Patients have consented, or a parent or legal guardian has consented on their behalf,
to be notified by the CNDR of research studies they may be eligible to participate
in.
3. Patients with a diagnosis of DMD confirmed by genetic testing or a muscle biopsy
demonstrating an absence of dystrophin protein, and a physician confirmed clinical
presentation consistent with DMD.
4. Patients are males.
5. Patients are between 5–17 years of age.
6. Patients have a parent available to complete a parent questionnaire.
Exclusion Criteria
1. Both patient and parent are unable to adhere to the study protocol (e.g. inability to
complete questionnaires, even with assistance, due to limited literacy, a
communication disorder or cognitive impairment).
2. Patient has a serious health condition or comorbidity unrelated to DMD, which may
influence study outcomes.
3.3

Data Collection Procedures
Data were collected using two sources: mailed paper questionnaires and registry data

collected during patients’ routine clinic visits. All data were de-identified. In accordance
with the CNDR protocol, all contacts with eligible patients were facilitated through the
CNDR National Office. No direct contacts were made with eligible patients or their parents
by research personnel to avoid unintended identification of patients or their parents.
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3.3.1

Mailed Questionnaires
Paper questionnaires were designed and mailed to eligible patients and their parent

in accordance with the Tailored Design Method, which was formulated using social
exchange theory as a rationale. Applied to questionnaire design and implementation, social
exchange theory assumes that the probability of responding to a questionnaire, and doing
so accurately, is greater when the respondent trusts that the perceived benefits outweigh
the perceived costs of responding [177]. In accordance with the Tailored Design Method,
a four-contact mailing strategy was used to maximize response rate. The four-contact
mailing strategy was executed between July 2016 and November 2016. Eligible patientparent pairs received (1) an initial questionnaire package, (2) a thank-you postcard one
week after the initial invitation (Appendix G), (3) a follow-up reminder letter (Appendix
H) with a replacement questionnaire package four weeks after the postcard, and (4) a final
reminder letter with replacement questionnaire package four weeks after the follow-up
reminder. Each questionnaire package included a letter of information (Appendix E), assent
letter (Appendix F), a postage-paid return envelope to minimize the cost of responding,
and two questionnaire booklets: one to be completed by the patient and one to be completed
by a parent. Three sets of questionnaires were designed using age-appropriate language
and instructions according to the following age groups: young children (5–7 years), older
children (8–12 years) and adolescents (13–17 years). Children and parents were instructed
to complete their respective questionnaires independently. If a patient was unable to
independently complete his questionnaire, the parent was instructed to read the questions
to the patient verbatim without providing interpretation, and to indicate the patient’s
answers in the questionnaire without providing guidance on how to respond. Parents of
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young children were instructed to act as interviewers for their child. A Tim Hortons gift
card valued at $5 CAD was included in the initial questionnaire package as a token of
appreciation for patient-parent pairs. Implied consent was assumed for patients and parents
who completed and returned questionnaires.
Questionnaire packages and thank-you postcards were compiled at Children’s
Hospital, London Health Sciences Centre in London, Ontario and forwarded to the CNDR
National Office. Unique identification numbers were generated for eligible patient-parent
pairs and used to label questionnaires by the CNDR National Office staff. Envelopes of
questionnaire packages and thank-you postcards were labeled with patient mailing
addresses and shipped to eligible patient-parent pairs by the CNDR National Office staff.
Completed questionnaires were initially returned by patient-parent pairs to the CNDR
National Office, and were then forwarded to Children’s Hospital, London Health Sciences
Centre by the CNDR National Office staff. If a questionnaire package was returned to
sender, an effort was made by the CNDR National Office staff to contact the patient’s clinic
to verify or obtain an updated mailing address for the patient.
3.3.2

Registry Data

Patient medical histories were retrieved from the CNDR database. Patient data included
in the CNDR database are collected prospectively at routine clinic visits through
standardized data collection forms completed by the physician or data-entry staff reviewing
patient medical records, followed by direct entry into the registry via a secure online entry
system. Patients without access to a participating neuromuscular clinic are required to sign
consent, assent and release of information forms to have their data submitted by their
healthcare provider. All data entry personnel are trained by the CNDR National Office
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staff. All data are encrypted and stored at the University of Calgary, and subject to
regulations for the protection of personal health information. Data entry is reviewed weekly
at the CNDR National Office to ensure data standard compliance; detected errors are
logged and reported to the site data-entry personnel for correction. Local data collection
forms are maintained as source documents and reviewed during annual audit visits by the
CNDR National Office staff. Participating individuals may withdraw their data from the
CNDR at any time [176].
Following data submission, patient-identifying information is separated from medical
information for de-identification. A unique identifier code is assigned and is the only link
between the two sets of information. The code is stored on a separate secure server and
accessible only by the site principal investigator and CNDR National Office staff. A dataset
of de-identified medical information, described below, was obtained for participating
patients who completed and returned questionnaires and non-participating patients who did
not complete and return questionnaires allowing for the assessment of whether clinical
characteristics of non-participating patients differed from participating patients [176].
3.4

Data Management
All completed questionnaires were securely stored at Children’s Hospital, London

Health Sciences Centre, where data were also cleaned and coded by the author using Stata®
13.0 Data Analysis and Statistical Software. Data from patient and parent questionnaires
were merged with registry data into a single Stata® 13.0 file in preparation for analysis
[178].
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3.5

Measures
Several measures for fatigue, physical activity level and depressive symptoms were

reviewed during selection of measures to be included in the patient and parent
questionnaires. Measures were selected based on validity, reliability and previous
administration in children and adolescents with DMD, neuromuscular disorders or physical
disabilities; appropriateness of measures for DMD patients according to clinical expertise;
factors associated with ease of administration and low participation burden, such as length
and use of developmentally appropriate language; and suitability for use in a mail-out
questionnaire and completion in an unsupervised setting.
3.5.1

Fatigue
Fatigue was measured using the Pediatric Quality of Life Inventory (PedsQLTM)

Multidimensional Fatigue Scale (MFS) [179]. The PedsQLTM Measurement Model was
developed to integrate generic and disease-specific modules to measure paediatric healthrelated quality of life (HRQOL). The generic module enables comparison of HRQOL
across patient and healthy populations, while disease-specific modules enhance sensitivity
for detecting and quantifying minimal clinically important differences [180,181]. The
PedsQLTM MFS was designed as a generic module to measure patient and parent
perceptions of fatigue in paediatric patients [179]. The PedsQLTM MFS was developed and
validated in paediatric oncology patients, and has since been validated in paediatric
hematology, rheumatology and endocrinology patients [117,118,179,182,183]. In addition,
the PedsQLTM MFS has been administered to paediatric nephrology, psychiatry and
neurology patients, including children and adolescents with DMD [3,14,58]. A recently
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published systematic review of instruments to assess fatigue in paediatric chronic health
conditions identified the PedsQLTM MFS as the most commonly used instrument [14].
The PedsQLTM MFS is available in child self-report formats for ages 5–17 and
parent proxy-report formats for ages 2–18 years. Parent proxy-report forms are parallel to
child self-report forms, and designed to assess parents’ perceptions of their child’s fatigue.
In this study, child self-report and parent proxy-report forms for ages 5–7 years (young
children), 8–12 years (older children) and 13–18 years (adolescents) were used. Items for
each form are essentially identical, differing only in developmentally appropriate language
for each age group, and first or third person as appropriate for child self-report and parent
proxy-report forms [117,118,179].
The PedsQLTM MFS is an 18-item form composed of three domains: General
Fatigue (six items), Sleep/Rest Fatigue (six items) and Cognitive Fatigue (six items). Items
include statements such as “I feel too tired to do things that I like to do” (General Fatigue),
“I feel tired when I wake up in the morning” (Sleep/Rest Fatigue) and “It is hard for me to
keep my attention on things” (Cognitive Fatigue). The instructions ask the respondent to
indicate how much of a problem each item has been in the past one month (Standard
Version) or seven days (Acute Version). The PedsQLTM MFS Standard Version (onemonth recall period) was used in the current study. A 5-point Likert scale is utilized across
child self-report forms for ages 8–18 years and parent proxy-report forms (0=never,
1=almost never, 2=sometimes, 3=often, and 4=almost always). To increase ease for young
children of ages 5–7 years, response options are simplified to a 3-point Likert scale (0=not
at all, 2=sometimes, and 4=a lot) anchored to a faces scale (0=happy face, 2=neutral face,
and 4=sad face). Items are reverse scored and linearly transformed to a scale of 0–100
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(0=100, 1=75, 2=50, 3=25, and 4=0), such that higher scores indicate fewer problems or
symptoms. Scores by domain are computed as the sum of items divided by the number of
items answered within the domain. In accordance with scoring instructions, if more than
50% of items in a domain is missing, the domain score was not computed. A total score is
computed as the sum of all items divided by the number of items answered on all domains.
For a total score to be computed, completion of 50% or more items is required
[117,118,179]. The PedsQLTM MFS child self-report and parent proxy-report forms are
presented in Appendices I and J, respectively.
3.5.2

Physical Activity Level
Physical activity measures may be broadly classified as objective or subjective.

Objective measures aim to quantify physiological and biomechanical parameters, and
estimate physical activity outcomes using methods such as accelerometry, pedometry or
heart rate monitoring. Subjective measures include survey measures, interviews and
activity diaries or logs [184,185]. A child self-report measure was used in the current study
because of low cost, ease of administration and low participation burden.
The Physical Activity Questionnaire for Children (PAQ-C) and Physical Activity
Questionnaire for Adolescents (PAQ-A) were used to measure physical activity level
(Appendix K) [186]. Reliability and validity have been reported as acceptable to good in
Canadian children and adolescents [187–189]. The PAQ-A has been previously
administered to adolescents with physical disability secondary to a neurologic disorder—
cerebral palsy [190]. The PAQ-C and PAQ-A measure physical activity level during the
past seven days [186]. The PAQ-C was designed for use in children in grades 4–8
(approximately 8–14 years of age) and the PAQ-A was designed for adolescents in grades
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9–12 (approximately 14–19 years of age). Questions in the PAQ-C were deemed applicable
for young children (5–7 years of age) in our study based on clinical paediatric expertise.
The PAQ-C was included in the patient questionnaire for young children and older
children, and the PAQ-A was included in the patient questionnaire for adolescents.
The PAQ-C is composed of nine items scored on a 5-point Likert scale. The first
item asks respondents to rate the frequency of participation in 22 common leisure and sport
activities and two “other” fill-in choices during the past seven days. This item is scored as
a mean of all activities. The remaining items ask respondents to rate their physical activity
level according to time-of-day or day-of-the-week. The PAQ-C summary score is the mean
of all nine items, with a score of 1 indicating low physical activity and score of 5 indicating
high physical activity. In the case of missing items, a summary score was not computed in
accordance with scoring instructions. The PAQ-A is composed of eight items and is
identical to the PAQ-C, except that the PAQ-A does not include an item concerning
physical activity during recess at school [186].
To improve applicability to DMD patients at all stages of the disease, modifications
were made to the PAQ-C and PAQ-A with permission from the developers. Items 3 and 4
in the original PAQ-C, and item 3 in the original PAQ-A provide the following response
options for rating physical activity during recess or lunch at school: 1=sat down (talking,
reading, doing school work), 2=stood around or walked around, 3=ran or played a little bit,
4=ran around and played quite a bit, and 5=ran and played hard most of the time. To
accommodate non-ambulatory children and adolescents, option 4 was modified to “ran
around or played quite a bit” and option 5 was modified to “ran or played hard most of the
time”. The mobility and strength of DMD patients may be limited, preventing participation
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in physical activity to the same extent as their healthy peers. Therefore, respondents were
instructed to consider any activity that causes them to sweat, breathe hard, or causes their
legs or arms to feel tired.
3.5.3

Functional Ability
Functional ability was assessed using the DMD Functional Ability Self-Assessment

Tool (DMDSAT; Appendix L), a patient- or parent-reported survey measure designed and
validated for assessing physical and respiratory functioning at all stages of disease
progression in patients with DMD. The DMDSAT is fit for measuring functional ability
from the early ambulatory to late non-ambulatory stage. The DMDSAT is composed of
eight items in four domains: arm function (one item), mobility (one item), transfers (five
items) and ventilatory support (one item). Each item asks respondents to rate their current
level of functioning related to common activities of daily living, upper and lower
extremities, or ventilation status. Item 1 is scored from 0–6, item 2 is scored from 0–5, and
items 3–8 are scored from 0–2. Higher scores indicating higher functional ability. A total
score is computed as the sum of all items, ranging from 0 (low functional ability) to 23
(high functional ability) [191]. In the case of missing items, a total score was computed by
dividing the sum of completed items by the maximum possible score of completed items,
and multiplying this fraction by the maximum possible score of all items, as advised by the
developer (Landfeldt, E., Personal Communication, May 2nd 2017). The DMDSAT was
included in the parent questionnaire; parents were instructed to complete the measure with
their child.
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3.5.4

Depressive Symptoms
Depressive symptoms were assessed using the Center for Epidemiological Studies

Depression Scale for Children (CES-DC; Appendix M)—a modified version of the Center
for Epidemiological Studies Depression Scale [192,193]. The CES-DC is a 20-item scale
comprising six symptom domains: depressive mood, feelings of guilt or worthlessness,
sense of helplessness or hopelessness, psychomotor retardation, loss of appetite and sleep
disturbance. Respondents are asked to indicate how strongly they experienced certain
feelings during the past week, using a 4-point Likert scale. Negatively phrased items are
scored as: 0=not at all, 1=a little, 2=some, and 3=a lot. Positively phrased items are reverse
scored as: 3=not at all, 2=a little, 1=some, and 0=a lot. A total score is computed as the
sum of all items and ranges from 0–60, with higher scores indicating greater depressive
symptoms [192,193]. In the case of missing items, a total score was computed after
imputing the mean of completed items as the response for missing items, as advised by the
developers (Fendrich, M. and Weissman, M., Personal Communication, April 27th, 2017).
The CES-DC has been validated for youth of ages 6–23 years, and is widely implemented
in research and clinical settings as a screening tool for depression [194]. Questions in the
CES-DC were deemed applicable for 5-year-old children with DMD included in our study
based on clinical paediatric expertise. The CES-DC has been previously used in children
and adolescents with physical disability secondary to a neurologic disorder—multiple
sclerosis [195]. The CESD-DC was included in the patient questionnaire. A child selfreport, rather than a parent proxy-report, measure of depressive symptoms was selected
because previous studies have demonstrated poor to moderate agreement between child
self-reported and parent proxy-reported internalizing problems, such as depressive
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symptoms [196–198]. Child self-reports of depressive symptoms are often more consistent
with formal psychiatric diagnoses of depression than parent proxy-reports [199,200].
3.5.5

Sleep Disturbance Symptoms
Sleep disturbance symptoms were assessed using the Sleep Disturbance Scale for

Children (SDSC; Appendix N). The SDSC is a 26-item parent proxy-report measure
encompassing six domains: disorders of initiating and maintaining sleep (seven items),
sleep-related breathing disorders (three items), disorders of arousal (three items), sleepwake transition disorders (six items), disorders of excessive somnolence (five items), and
sleep hyperhidrosis (two items). In answering questions, respondents are asked to consider
their child’s sleep behaviour during the past six months. Using a 5-point Likert scale,
respondents indicate how frequently certain behaviours are exhibited by their child:
1=never, 2=occasionally (once or twice per month or less), 3=sometimes (once or twice
per week), 4=often (3 or 5 times per week), and 5=always (daily). Respondents are also
asked to provide estimates of sleep quantity and sleep onset latency. Domain scores are
computed as the sum of items within each domain. A total score is computed as the sum of
domain scores, and ranges from 26–130. Higher scores indicate greater sleep disturbance
symptoms. In the case of missing items, the domain score and total score were not
computed as advised by the developer (Bruni, O., Personal Communication, April 27th,
2017). The SDSC was designed for use in research and clinical settings, and has been
validated in healthy and patient populations of ages 6–15 years [201]. The SDSC has
previously been used in children and adolescents with DMD of ages 4–18 years [72]. The
SDSC was included in the parent questionnaire.
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3.5.6

Patient Medical Information
Patient medical histories were retrieved from the CNDR for both participating and

non-participating patients. The patient’s age (years) as of June 13th, 2016 was obtained
from the CNDR. Musculoskeletal characteristics retrieved from the CNDR included:
unsupported ambulatory status (ambulant, non-ambulant), unsupported sitting ability status
(yes, no), wheelchair use (never, intermittent or permanent), scoliosis status (none,
surgically corrected, or uncorrected), corticosteroid therapy status (never, past, or current),
and corticosteroid type (deflazacort or prednisone). Respiratory characteristics retrieved
from the CNDR included: forced vital capacity (%), non-invasive ventilatory status (never,
part-time, or full-time) and invasive ventilatory status (never, part-time, or full-time).
Cardiac characteristics retrieved from the CNDR included: left ventricular ejection fraction
(%), cardiomyopathy status (yes, no) and use of cardiac medications (yes, no).
In addition to patient medical histories retrieved from the CNDR, a patient medical
information section was included in the parent questionnaire (Appendix O). The patient
medical information questionnaire was adapted from the Health-Related Quality of Life in
Children with Epilepsy Study (HERQULES), with permission from the principal
investigator [202]. Parents reported the presence of serious health conditions or comorbidities unrelated to DMD, such as cystic fibrosis, diabetes, cerebral palsy, epilepsy
and cancer. Parents reported whether their child had been formally diagnosed with any of
the following neuropsychiatric disorders: developmental delay, learning disability,
attention deficit disorder, attention hyperactivity deficit disorder, autism spectrum disorder,
oppositional defiant disorder, conduct disorder, depression and anxiety. To evaluate the
relationship between neuropsychiatric disorders and fatigue, a single binary variable was

59
used: diagnosis with one or more neuropsychiatric disorder. Parents reported whether their
child has ever needed and ever received: pharmacological or psychotherapy for behavioural
or emotional problems, speech language therapy, occupational therapy, and special
education. Lastly, parents reported their child’s ambulatory status (ambulant, nonambulant) and if applicable, time since loss of ambulation (less than one year ago, or one
year ago or more). Parent-reported non-invasive ventilatory status was also extracted from
DMDSAT. Where possible medical information of participating patients retrieved from the
CNDR was cross-referenced with parent-report medical information (ambulatory status
and non-invasive ventilatory status). In the case of discrepancies between registry and
parent-reported medical information, the most recently dated information available was
used, which was parent-reported information in all cases. Discrepant information was
reviewed by a paediatric neurologist to ensure the most recently dated information was
reflective of the progressive functional decline of the disease and interpreted in the context
of other clinical characteristics.
3.5.7

Sociodemographic Information
A sociodemographic information section was included in the parent questionnaire

(Appendix P). Parents reported their age, sex, relationship to the patient, highest
educational attainment, employment status and marital status. If applicable, parents
reported the highest educational attainment and employment status of their spouse or
partner. Lastly, household size and annual household income before taxes (CAD) were
collected by parent-report.
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3.6

Statistical Analyses
All statistical analysis was performed using Stata® 13.0 [178]. A two-sided level of

significance at =0.05 was assumed.
3.6.1

Sample Characteristics
Descriptive statistics were computed for patient medical information and

sociodemographic information. Mean  standard deviation or median (interquartile range),
minimum and maximum were computed for continuous variables. Frequencies and
percentages were computed for categorical variables. To assess differences between
participating and non-participating patients, unpaired two-sample t-tests were used for
continuous variables, and 2 tests of independence or Fisher’s exact tests were used for
categorical variables. Fisher’s exact tests were used in place of 2 tests of independence
when an expected frequency in a response category was less than 5.
3.6.2

Objective 1: To describe subjective fatigue in children and adolescents with DMD
from patients’ and parents’ perspectives.
Distributions of child self-report and parent proxy-report PedsQLTM MFS scores

were assessed using graphical methods (normal quantile-quantile plots, box-and-whisker
plots and histograms) and statistical methods (Shapiro-Wilk test of normality). Descriptive
statistics were computed for child self-report and parent proxy-report PedsQLTM MFS
scores for the total sample and for subgroups according to age (young children, 5–7 years;
older children, 8–12 years; and adolescents, 13–17 years) and ambulatory status (ambulant
and non-ambulant). Mean  standard deviation, median (interquartile range), minimum and
maximum were computed for total fatigue, general fatigue, sleep/rest fatigue and cognitive
fatigue scores. PedsQLTM MFS scores of DMD patients in the current study were compared
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with PedsQLTM MFS scores of healthy children and adolescents from published data
[117,118]. Agreement between child self-reports and parent proxy-reports of PedsQLTM
MFS scores were examined using pairwise correlation analyses with Pearson’s correlation
coefficient (r), or Spearman’s rank correlation coefficient (ρ) if non-normality of data was
observed.
3.6.3

Objective 2: To explore associations of patient characteristics with child self-report
and parent proxy-report measures of subjective fatigue in children and adolescents
with DMD.
Bivariate analyses were conducted to explore associations of patient characteristics

with child self-reported and parent proxy-reported fatigue. For dichotomous variables
(ambulatory status, time since loss of ambulation, current glucocorticoid use,
cardiomyopathy, diagnoses with one or more neuropsychiatric disorder), unpaired twosample t-tests or non-parametric Wilcoxin Rank Sum tests were used to assess differences
in PedsQLTM MFS scores between categories. Wilcoxin Rank Sum tests were used in place
of unpaired two-sample t-tests when n<30 in one or more category or normality of the
PedsQLTM MFS score was violated. For categorical variables of more than two categories
(age group, wheelchair use, scoliosis and non-invasive ventilatory status), one-way
analysis of variance (ANOVA) or non-parametric Kruskal-Wallis tests were used to assess
differences in PedsQLTM MFS scores between categories. Kruskal-Wallis tests were used
in place of one-way ANOVA when n<30 in one or more category or normality of the
PedsQLTM MFS score was violated.
Distributions of continuous variables were assessed using graphical methods
(normal quantile-quantile plots, box-and-whisker plots and histograms) and statistical

62
methods (Shapiro-Wilk test of normality). Relationships of continuous variables (age,
physical activity level, functional ability, depressive symptoms, sleep disturbance
symptoms, forced vital capacity and left ventricular ejection fraction) with PedsQLTM MFS
scores were visually inspected using scatter plots. Associations of continuous variables
with PedsQLTM MFS scores were examined using pairwise correlation analyses with
Pearson’s correlation coefficient (r), or Spearman’s rank correlation coefficient (ρ) if nonnormality of the data was observed.
Multivariable linear regression analyses were used to further explore the
association between total sleep disturbance symptoms with child self-reported and parent
proxy-reported fatigue, while adjusting for additional patient characteristics. Given the
exploratory nature of this thesis, bivariate analyses and clinical expertise were used to guide
selection of patient characteristics to be adjusted for in the linear regression analyses, as
described in Chapter 4 (Results). Linear regression analyses were initially performed with
complete case analysis (listwise deletion), followed by linear regression analyses with
multiple imputation using chained equations as a sensitivity analysis for examining the
impact of missing data. Normally distributed continuous variables were imputed using
linear regression. Non-normally distributed continuous variables were imputed using
predictive mean matching [203,204].
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Chapter 4
4
4.1

Results
Sample Characteristics
A total of 193 eligible participants, composed of 26 young children (13.5%; ages

5–7 years), 75 older children (38.9%; ages 8–12 years) and 92 adolescents (47.7%; ages
13–17 years), were identified through the Canadian Neuromuscular Disease Registry
(CNDR) and received mailed paper questionnaires. An overall response rate of 36.8% was
achieved, with N=71 eligible patient-parent pairs returning completed questionnaires.
Questionnaire packages were returned to sender for seven patients for whom mailing
addresses could not be corrected by contacting their clinic. Participating patients included
12 young children (16.9%), 25 older children (35.2%) and 34 adolescents (47.9%). Both
patient and parent questionnaires were completed by 64 patient-parent pairs, while for five
participants only the parent questionnaire was completed and for two participants only the
patient questionnaire was completed. No patients were excluded due to a parent-reported
comorbidity unrelated to Duchenne muscular dystrophy (DMD). One parent answered
“Yes” to their child having all comorbidities: asthma, cystic fibrosis, diabetes, cerebral
palsy, epilepsy and cancer. Based on clinical judgement, however, this was assumed to be
a response error and the patient was included. Three additional patients were reported to
have asthma. These patients were included under the assumption that their asthma was
well-managed due to routine clinical respiratory care typically received by DMD patients.
Additionally, asthma may be an adverse effect of medications used in the cardiac
management of DMD, such as angiotensin-converting enzyme inhibitors or betaadrenergic blocking agents [205].
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4.1.1

Comparison of Participating and Non-Participating Patients
Patient medical histories were retrieved from the CNDR for both participating and

non-participating patients, and are summarized in Table 4.1. No statistically significant
differences were observed between participating and non-participating patients with
respect to any clinical characteristic examined: age, genetic mutation, musculoskeletal
characteristics (unsupported ambulation, unsupported sitting ability, wheelchair use,
scoliosis and corticosteroid use), respiratory characteristics (forced vital capacity and noninvasive and invasive ventilatory support) and cardiac characteristics (left ventricular
ejection fraction, cardiomyopathy status and cardiac medications), and clinical trial
participation. Additionally, no statistically significant difference was observed between
participating and non-participating patients with respect to geographic region in Canada
(Table 4.1).
4.1.2

Patient Medical Information
In addition to patient medical histories from the CNDR, parents of participating

patients completed a patient medical information questionnaire as summarized in Table
4.2. On average, participating patients were 11.6  3.6 years of age (mean  standard
deviation), and ranged from 5–17 years of age. Most patients had a deletion (60.6%) in the
DMD gene, followed by a duplication (16.9%) or point mutation (16.9%). More than half
of patients were ambulant (59.2%). Among non-ambulant patients, the majority lost
ambulation more than one year ago (74.1%). Most patients did not have scoliosis (64.8%).
Most patients were currently receiving corticosteroid therapy (73.2%). Of patients
currently receiving corticosteroid therapy, most were receiving deflazacort (90.2%). On
average, forced vital capacity of patients was 85.2  18.3% (mean  standard deviation),
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and ranged from 50–127%. Four patients (5.6%) were receiving non-invasive ventilatory
support either part-time (N=2) or full-time (N=2). No patients were receiving invasive
ventilatory support. On average, left ventricular ejection fraction of patients was 63.3 
7.0% (mean  standard deviation), and ranged from 48–76%. Five patients (7%) were
diagnosed with cardiomyopathy. More than half of children have been diagnosed with at
least one neuropsychiatric disorder (53.5%). A learning disability was the most commonly
reported neuropsychiatric disorder (33.8%), followed by developmental delay (22.5%),
attention deficit disorder or attention deficit hyperactivity disorder (15.5%) and anxiety
(12.7%).
4.1.3

Sociodemographic Information
A sociodemographic information questionnaire was completed by parents as

summarized in Table 4.3. On average, parents of participating patients were 44.6  6.3
years of age (mean  standard deviation), and ranged from 29–56 years of age. Of the
primary caregivers who completed the parent questionnaire, 84.5% were female and 94.4%
were the child’s biological parent. Most parents completed post-secondary education
(70.4%), and more than half were employed either part-time or full-time (60.6%). Most
parents were married or living common law (71.8%). Median annual household income
before taxes was $75,000 to $99,999 CAD, which is consistent with the national median
household income [206].
4.2

Objective 1: To describe subjective fatigue in children and adolescents with
DMD from patients’ and parents’ perspectives.
Descriptive statistics for child-self report and parent proxy-report Pediatric Quality

of Life Inventory InventoryTM (PedsQLTM) Multidimensional Fatigue Scale (MFS) scores
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are summarized in Tables 4.4–4.6 for all respondents, by age group, and by ambulatory
status, respectively. Possible PedsQLTM MFS scores range from 0–100 for total fatigue,
general fatigue, sleep/rest fatigue and cognitive fatigue, with higher scores indicating less
fatigue [118]. For reference, data from the current study were compared to PedsQLTM MFS
scores of healthy children and adolescents from published data (Table 4.4). On average,
healthy children and adolescents were 13.7  2.2 years of age (mean  standard deviation),
and ranged from 10–17 years of age. The healthy sample included 74 males (47.1%) and
83 females (52.9%) [118]. PedsQLTM MFS scores were also compared to published data
from a second healthy sample, which included younger children of ages 8.9  11.0 years
(mean  standard deviation) ranging from 2–18 years. The healthy sample was composed
of 69 males (67.6%) and 33 females (32.4%) who were administered the PedsQLTM MFS
Acute Version (seven-day recall period) [117].
4.2.1

PedsQLTM Multidimensional Fatigue Scale by Child Self-Report
Children and adolescents with DMD reported greater fatigue (lower scores)

compared with healthy children and adolescents from published data across all domains,
irrespective of age group or ambulatory status [117,118]. The average fatigue score by
child self-report was 71.6  15.2 (mean  standard deviation). Median general fatigue score
by child self-report was 70.8, with an interquartile range of 58.3–83.3. Median sleep/rest
fatigue score by child self-report was 75 with an interquartile range of 64.6–87.5. Median
cognitive fatigue score by child self-report was 70.8, with an interquartile range of 54.2–
91.7. The trajectory of child self-reported fatigue across disease stages was examined
through PedsQLTM MFS scores stratified by age group (Table 4.5) and ambulatory status
(Table 4.6). Older children tended to report greater total fatigue compared with young
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children and adolescents. Older children and adolescents tended to report greater general
fatigue and sleep/rest fatigue compared with young children. Young children and older
children tended to report greater cognitive fatigue compared with adolescents. Ambulant
and non-ambulant patients reported similar total fatigue and sleep/rest fatigue. Nonambulant patients tended to report greater general fatigue compared with ambulant
patients. Ambulant patients tended to report greater cognitive fatigue compared with nonambulant patients.
4.2.2

PedsQLTM Multidimensional Fatigue Scale by Parent Proxy-Report
PedsQLTM MFS scores by child self-report were significantly correlated with

PedsQLTM MFS scores by parent proxy-report across domains (Table 4.7): total fatigue
(ρ=0.69; P<0.001), general fatigue (ρ=0.63; P<0.001), sleep/rest fatigue (ρ=0.50; P<0.001)
and cognitive fatigue (ρ=0.68; P<0.001). However, parents perceived their child’s level of
general fatigue to be worse than that perceived by the patient. Children and adolescents
with DMD experienced greater fatigue (lower scores) by parent proxy-report compared
with healthy children and adolescents from published data across all domains, irrespective
of age group or ambulatory status [117,118]. The average total fatigue score by parent
proxy-report was 70.8  16.0 (mean  standard deviation). General fatigue scores by parent
proxy-report were 64.2  20.1 (mean  standard deviation). Median sleep/rest fatigue score
by parent proxy-report was 79.2 with an interquartile range of 66.7–91.7. Median cognitive
fatigue score by parent proxy-report was 75, with an interquartile range of 54.2–91.7. The
trajectory of parent proxy-reported fatigue across disease stages was examined through
PedsQLTM MFS scores stratified by age group (Table 4.5) and ambulatory status (Table
4.6). Parents reported that older children tended to experience greater total fatigue
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compared with young children and adolescents. According to parents, older children and
adolescents tended to experience greater general fatigue and sleep/rest fatigue compared
with young children. Young children and older children tended to experience greater
cognitive fatigue with adolescents. Ambulant and non-ambulant patients experienced
similar total fatigue. Non-ambulant patients tended to experience greater general fatigue
and sleep/rest fatigue compared with ambulant patients. Ambulant patients tended to
experience greater cognitive fatigue compared with non-ambulant patients.
4.3

Objective 2: To explore associations of patient characteristics with child selfreport and parent parent-proxy report measures of subjective fatigue in
children and adolescents with DMD.

4.3.1

Age
Age was assessed as a categorical variable (young children, older children,

adolescents) and a continuous variable. Age group was not significantly associated with
any child self-report or parent proxy-report measure of fatigue (Table 4.5). Similarly, age
(years) was not significantly correlated with any measure of fatigue by child self-report
(Table 4.8) or parent proxy-report (Table 4.9).
4.3.2

Musculoskeletal Characteristics
No significant differences were observed between ambulant and non-ambulant

patients for total fatigue, general fatigue, sleep/rest fatigue or cognitive fatigue by child
self-report or parent proxy-report (Table 4.6).
Among non-ambulant patients, no significant differences were observed between
patients who lost ambulation less than one year ago compared with patients who lost
ambulation one year ago or more for total fatigue by child self-report (Z=-0.85; P=0.40) or
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parent proxy-report (Z=-0.22; P=0.82); general fatigue by child self-report (Z=-1.18;
P=0.24) or parent proxy-report (Z=-0.69; P=0.49); sleep/rest fatigue by child self-report
(Z=0.34; P=0.73) or parent proxy-report (Z=0.39; P=0.70); and cognitive fatigue by child
self-report (Z=-0.58; P=0.56) or parent proxy-report (Z=-0.31; P=0.76).
No significant differences were observed among patients who never, intermittently
or permanently use a wheelchair for total fatigue by child self-report (2=0.37; P=0.83) or
parent proxy-report (2=3.15; P=0.21); general fatigue by child self-report (2=2.73;
P=0.26) or parent proxy-report (2=4.24; P=0.12); sleep/rest fatigue by child self-report
(2=0.54; P=0.76) or parent proxy-report (2=4.48; P=0.11); and cognitive fatigue by child
self-report (2=1.89; P=0.39) or parent proxy-report (2=2.06; P=0.36).
No significant differences were observed among patients without scoliosis, with
surgically corrected scoliosis, or with uncorrected scoliosis for total fatigue by child selfreport (2=0.75; P=0.69) or parent proxy-report (2=4.11; P=0.13); general fatigue by child
self-report (2=0.86; P=0.65) or parent proxy-report (2=1.94; P=0.38); sleep/rest fatigue
by child self-report (2=0.03; P=0.98) or parent proxy-report (2=1.33; P=0.51); and
cognitive fatigue by child self-report (2=1.87; P=0.39) or parent proxy-report (2=4.25;
P=0.12).
Ten patients (14.1%) in our sample were not currently receiving glucocorticoid
therapy. However, current glucocorticoid use was not associated with total fatigue by child
self-report (Z=-0.04; P=0.97) or parent proxy-report (Z=-0.02; P=0.98); general fatigue by
child self-report (Z=1.77; P=0.08) or parent proxy-report (Z=0.74; P=0.46); sleep/rest
fatigue by child self-report (Z=-0.84; P=0.40) or parent proxy-report (Z=0.98; P=0.33); and
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cognitive fatigue by child self-report (Z=-0.95; P=0.34) or parent proxy-report (Z=-0.65;
P=0.53).
4.3.3

Respiratory Characteristics
Greater forced vital capacity was significantly associated with less general fatigue

by child self-report (ρ=0.34; P=0.03). Forced vital capacity was not associated with other
domains of fatigue by child self-report (Table 4.8) or parent-proxy report (Table 4.9).
Kruskal-Wallis test demonstrated a significant difference in parent proxy-reported
sleep/rest fatigue between patients not treated with non-invasive ventilation (NIV; N=66),
patients treated with part-time NIV (N=2) and patients treated with full-time NIV (N=2;
2=7.02; P=0.03). Post-hoc analysis using Dunn’s test with Bonferroni adjustment
demonstrated that parent proxy-reported sleep/rest fatigue was stochasticity greater for
patients treated with part-time NIV compared with children not treated with NIV (P=0.03).
Sleep/rest fatigue scores of the two patients receiving part-time NIV were 8.3 and 54.2 by
parent proxy-report, and 8.3 and 66.7 by child self-report. In comparison, the median
sleep/rest fatigue score of the entire sample was 79.2 by parent proxy-report and 75 by
child self-report. Total fatigue scores of the two patients receiving part-time NIV were 63.9
and 58.3 by parent proxy-report, and 44.4 and 63.9 by child self-report. In comparison, the
mean total fatigue score of the entire sample was 70.8 by parent proxy-report and 71.6 by
child self-report.
NIV status was not associated with total fatigue by child self-report (2=0.4.25;
P=0.12) or parent proxy-report (2=0.98; P=0.61); general fatigue by child self-report
(2=2.38; P=0.30) or parent proxy-report (2=2.58; P=0.27); sleep/rest fatigue by child
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self-report (2=2.95; P=0.23); and cognitive fatigue by child self-report (2=1.80; P=0.41)
or parent proxy-report (2=0.40; P=0.82).
4.3.4

Cardiac Characteristics
Left ventricular ejection fraction was not associated with any measure of fatigue by

child self-report (Table 4.8) or parent-proxy report (Table 4.9). Patients with
cardiomyopathy (N=5) had stochastically less cognitive fatigue compared with patients
without cardiomyopathy (N=59) by child self-report (Z=-2.39; P=0.02) and parent proxyreport (Z=-2.11; P=0.04). Cardiomyopathy status was not associated with total fatigue by
child self-report (Z=-0.22; P=0.83) or parent proxy-report (Z=-1.13; P=0.26); general
fatigue by child self-report (Z=1.01; P=0.31) or parent proxy-report (Z=0.71; P=0.48); and
sleep/rest fatigue by child self-report (Z=0.33; P=0.74) or parent proxy-report (Z=0.31;
P=0.76).
4.3.5

Neuropsychiatric Characteristics
Diagnosis with one or more neuropsychiatric disorder was not associated with total

fatigue by child self-report (t=0.85; P=0.40) or parent proxy-report (t=1.93; P=0.06);
general fatigue by child self-report (t=1.50; P=0.14) or parent proxy-report (t=0.92;
P=0.36); sleep/rest fatigue by child self-report (t=0.47; P=0.64) or parent proxy-report
(t=1.87; P=0.07); and cognitive fatigue by child self-report (t=-0.05; P=0.96) or parent
proxy-report (t=1.82; P=0.07).
4.3.6

Physical Activity Level
Physical activity level was measured using the Physical Activity Questionnaire for

Children and Adolescents (PAQ-C/A). Possible PAQ-C/A scores range from 1 (low
physical activity) to 5 (high physical activity) [187]. Median PAQ-C/A score was 1.7, with
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an interquartile range of 1.3–2.3 and range of 1–3.7. Greater physical activity was
significantly associated with less general fatigue (ρ=0.27; P=0.04) by child self-report.
Physical activity level was not associated with other domains of fatigue by child self-report
(Table 4.8) or parent-proxy report (Table 4.9).
4.3.7

Functional Ability
Overall functional ability was measured using the Duchenne Muscular Dystrophy

Functional Ability Self-Assessment Tool (DMDSAT). Possible DMDSAT scores range
from 0 (low functional ability) to 23 (high functional ability) [191]. Median DMDSAT
score was 18, with an interquartile range of 9–21 and range of 3–23. Lower functional
ability was significantly associated with greater total fatigue by parent proxy-report only
(ρ=0.26; P=0.03); with greater general fatigue by child self-report (ρ=0.30; P=0.02) and
parent proxy-report (ρ=0.30; P=0.01); and with greater sleep/rest fatigue by parent proxyreport only (ρ=0.35; P=0.003). Functional ability was not associated with cognitive fatigue
by child self-report (Table 4.8) or parent proxy-report (Table 4.9).
4.3.8

Depressive Symptoms
Depressive symptoms were measured using the Center for Epidemiological Studies

Depression Scale for Children (CES-DC). Possible CES-DC scores range from 0–60 with
higher scores indicating greater depressive symptoms [193,207]. Median CES-DC score
was 7.5, with an interquartile range of 4–15 and range of 0–45. More depressive symptoms
were significantly associated with greater total fatigue by child self-report (ρ=-0.46;
P<0.001) and parent proxy-report (ρ=-0.45; P<0.001); with greater general fatigue by child
self-report (ρ=-0.30; P=0.02) and parent proxy-report (ρ=-0.37; P=0.002); with greater
sleep/rest fatigue by child self-report (ρ=-0.30; P=0.02) and parent proxy-report (ρ=-0.35;
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P=0.005); and with greater cognitive fatigue by child self-report (ρ=-0.46; P<0.001) and
parent proxy-report (ρ=-0.32; P=0.009).
4.3.9

Sleep Disturbances Symptoms
Sleep disturbance symptoms were measured using the Sleep Disturbance Scale for

Children (SDSC), composed of six sleep disturbance factors: disorders of initiating and
maintaining sleep, sleep-related breathing disorders, disorders of arousal, sleep-wake
transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis. Factor
scores and total scores were computed. Possible SDSC total scores range from 26–130,
with higher scores indicating greater sleep disturbance symptoms [201]. Median SDSC
total score was 38, with an interquartile range of 33–41 and range of 28–81. More sleep
disturbance symptoms were significantly associated with greater total fatigue by child selfreport (ρ=-0.42; P=0.003) and parent proxy-report (ρ=-0.51; P<0.001); with greater
general fatigue by child self-report (ρ=-0.32; P=0.03) and parent proxy-report (ρ=-0.45;
P=0.001); with greater sleep/rest fatigue by child self-report (ρ=-0.30; P=0.04) and parent
proxy-report (ρ=-0.48; P<0.001); and with greater cognitive fatigue by child self-report
(ρ=-0.33; P=0.03) and parent proxy-report (ρ=-0.34; P=0.01). Spearman’s rank correlation
coefficients for each SDSC factor score and PedsQLTM MFS scores by child self-report and
parent proxy-report are presented in Table 4.8 and Table 4.9, respectively. Significant
correlations with fatigue were most frequently observed for disorders of initiating and
maintaining sleep, disorders of arousal, sleep/wake transition disorders, and disorders of
excessive somnolence.
Exploratory multivariable linear regression analyses were performed to test the
association between total sleep disturbance symptoms with child self-reported fatigue and
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parent proxy-reported fatigue, while adjusting for physical activity level, functional ability
and depressive symptoms (Figure 4.1). Because bivariate analyses did not consistently
demonstrate significant associations between objective measures of musculoskeletal,
respiratory and cardiac function and fatigue, overall functional ability may be more related
to fatigue than any single musculoskeletal, respiratory or cardiac characteristic. Thus,
functional ability measured using the DMDSAT was included as a covariate in the
multivariable linear regression analyses, rather than single measures of musculoskeletal,
respiratory and cardiac function. Although cardiac function is not reflected in the
DMDSAT score, it was not included as a covariate because clinical manifestation of
cardiac dysfunction that may impact fatigue are more likely to present in adulthood than in
childhood or adolescence [94].

Figure 4.1. A model of fatigue in children and adolescents with Duchenne muscular
dystrophy tested using multivariable linear regression analyses.
Linear regression analyses with listwise deletion are presented in Tables 4.10 and
4.11 for child self-reported and parent proxy-reported fatigue, respectively (N=41). More
sleep disturbance symptoms were significantly associated with greater child self-reported
total fatigue (=-0.84; P=0.001), general fatigue (=-0.97; P=0.003) and cognitive fatigue
(=-1.24; P=0.006), but not with child self-reported sleep/rest fatigue (=-0.28; P=0.31),
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while adjusting for physical activity level, functional ability and depressive symptoms
(Table 4.10). Sleep disturbance symptoms, physical activity level, functional ability and
depressive symptoms explained 38% of the variability in child self-reported total fatigue,
39% of the variability in child self-reported general fatigue, and 22% of the variability in
child self-reported cognitive fatigue. More sleep disturbance symptoms were significantly
associated with parent proxy-reported total fatigue (=-0.91; P<0.001), general fatigue
(=-1.08; P=0.002), sleep/rest fatigue (=-0.62; P=0.01) and cognitive fatigue (=-1.03;
P=0.02), while adjusting for physical activity level, functional ability and depressive
symptoms (Table 4.11). Sleep disturbance symptoms, physical activity level, functional
ability and depressive symptoms explained 44% of the variability in parent proxy-reported
total fatigue, 32% of the variability in parent proxy-reported general fatigue, 32% of the
variability in parent proxy-reported sleep/rest fatigue, and 18% of the variability in parent
proxy-reported cognitive fatigue.
Linear regression analyses with multiple imputation using chained equations
performed to examine the impact of missing data are presented in Tables 4.12 and 4.13 for
child self-reported and parent proxy-reported fatigue, respectively (N=71). This sensitivity
analysis yielded similar results for child self-reported and parent proxy-reported fatigue
compared with the analysis using listwise deletion. More sleep disturbance symptoms were
significantly associated with greater child self-reported total fatigue (=-0.62; P=0.008),
general fatigue (=-0.73; P=0.03) and cognitive fatigue (=-0.94; P=0.005), but not with
child self-reported sleep/rest fatigue (=-0.17; P=0.60), while adjusting for physical
activity level, functional ability and depressive symptoms (Table 4.12). More sleep
disturbance symptoms were significantly associated with parent proxy-reported total
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fatigue (=-0.66; P=0.03), general fatigue (=-0.74; P=0.04), but not with sleep/rest
fatigue (=-0.39; P=0.27) or cognitive fatigue (=-0.73; P=0.10), while adjusting for
physical activity level, functional ability and depressive symptoms (Table 4.13). Although
the associations between sleep disturbance symptoms and parent proxy-reported sleep/rest
fatigue and cognitive fatigue were no longer significant, the direction of the regression
coefficients remained the same with more sleep disturbance symptoms being associated
with greater fatigue.
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Table 4.1. Comparison of clinical characteristics retrieved from the Canadian
Neuromuscular Disease Registry between participating and non-participating patients
Participating
Non-Participating
P-Valuea
Patients
Patients
(N=71)
(N=122)
Region
0.18
British Columbia
13 (18.3%)
36 (29.5%)
Alberta
10 (14.1%)
15 (12.3%)
Ontario
40 (56.4%)
65 (53.3%)
Quebec
8 (11.3%)
6 (4.9%)
Age
0.56
11.6  3.6
12.0  3.3
(5, 17)
(5, 17)
Genetic Mutation
0.32
Deletion
43 (60.6%)
82 (67.2%)
Duplication
12 (16.9%)
10 (8.2%)
Point Mutation
12 (16.9%)
19 (15.6%)
None Detected
1 (1.4%)
3 (2.5%)
Unreported
3 (4.2%)
8 (6.6%)
Musculoskeletal Characteristics
Unsupported ambulation
0.45
Ambulant
42 (59.2%)
84 (68.9%)
Non-ambulant
28 (39.4%)
31 (25.4%)
Unreported
1 (1.4%)
7 (5.7%)
Unsupported sitting ability
0.75
No
4 (5.6%)
6 (4.9%)
Yes
57 (80.3%)
104 (83.3%)
Unreported
10 (14.1%)
12 (9.8%)
Wheelchair use
0.50
Never
30 (42.3%)
47 (38.5%)
Intermitted
16 (22.5%)
38 (31.1%)
Permanent
17 (23.9%)
27 (22.1%)
Unreported
8 (11.3%)
10 (8.2%)
Scoliosis
0.92
No
46 (64.8%)
82 (67.2%)
Surgically corrected
1 (1.4%)
1 (0.8%)
Uncorrected
9 (12.7%)
19 (15.6%)
Unreported
15 (21.1%)
20 (16.4%)
Corticosteroid therapy
0.25
Never
9 (12.7%)
8 (6.6%)
Past
1 (1.4%)
2 (1.6%)
Current
52 (73.2%)
101 (82.8%)
Unreported
9 (12.7%)
11 (9.0%)
Corticosteroid type
0.60
Deflazacort
47 (90.4%)
95 (96.0%)
Prednisone
2 (3.9%)
2 (2.0%)
Unreported
3 (5.8%)
2 (2.0%)

78

Forced vital capacity
Non-invasive ventilatory
support
No
Part-time
Full-time
Unreported
Invasive ventilatory support
No
Part-time
Full-time
Unreported

Participating
Non-Participating
Patients
Patients
(N=71)
(N=122)
Respiratory Characteristics
85.2  18.3
80.6  23.0
(50, 127)
(16, 135)

P-Valuea

0.28
0.15

66 (93.0%)
2 (2.8%)
2 (2.8%)
1 (1.4%)

105 (86.1%)
6 (4.9%)
11 (9.0%)
-

62 (87.3%)
109 (89.3%)
9 (12.7%)
13 (10.7%)
Cardiac Characteristics
Left ventricular ejection fraction
0.85
63.3  7.0
62.9  9.9
(48, 76)
(17.4, 80)
Cardiomyopathy
0.50
No
59 (83.1%)
106 (86.9%)
Yes
5 (7.0%)
5 (4.1%)
Unreported
7 (9.9%)
11 (9.0%)
Cardiac medications
0.78
No
46 (64.8%)
91 (74.6%)
Yes
13 (18.3%)
23 (18.9%)
Unreported
12 (16.9%)
8 (6.6%)
Research
Clinical trial participation
0.31
Never
35 (49.3%)
70 (57.4%)
Past
1 (1.4%)
7 (5.7%)
Current
15 (21.1%)
21 (17.2%)
Unreported
20 (28.2%)
24 (19.7%)
Data are mean  standard deviation (range) or frequency (percentage)
a
Unpaired t-tests were used for continuous variables, and 2 tests or Fisher’s exact tests
were used for categorical variables to assess differences between respondents and nonrespondents. Unreported values were not included in analyses.

79
Table 4.2. Patient medical information by parent-report (respondents only, N=71)
Frequency Percentage
Motor Function
Ambulant
42
59.2%
Non-ambulant
28
39.4%
Lost ambulation less than one year ago
7
25.0%
Lost ambulation one year ago or more
20
71.4%
Neuropsychiatric Disorders
Developmental delay
16
22.5%
Learning disability
24
33.8%
Attention Deficit Disorder or Attention Deficit Hyperactivity
11
15.5%
Disorder
Autism spectrum disorder
1
1.4%
Oppositional defiant disorder
4
5.6%
Conduct disorder
2
2.8%
Depression
5
7.0%
Anxiety
9
12.7%
One or more neuropsychiatric disorder
38
53.5%
Therapies
Pharmacotherapy or psychotherapy for behavioural problems
Ever needed
14
19.7%
Ever received
12
16.9%
Pharmacotherapy or psychotherapy for emotional problems
Ever needed
12
16.9%
Ever received
11
15.5%
Occupational therapy
Ever needed
44
62.0%
Ever received
42
59.2%
Speech language therapy
Ever needed
26
36.6%
Ever received
26
36.6%
School Information
Special education (individualized education plan, special
needs classroom, tutoring, etc.)
Ever needed
50
70.4%
Ever received
47
66.2%
Research
Current clinical trial or other research participation
31
44.9%
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Table 4.3. Sociodemographic information by parent-report (respondents only, N=71)
Frequency
Percentage
Primary Caregivera
Age
(29, 56)b
44.6  6.3b
Sex
Male
9
12.8%
Female
60
84.5%
Relationship to Child
Biological parent
67
94.4%
Adoptive parent
Step parent
Foster parent
2
2.8%
Guardian
Highest educational attainment
Less than secondary school graduation
5
7.1%
Secondary school diploma or equivalent
13
18.3%
Vocational training
7
9.9%
College or university diploma or degree
38
53.5%
Graduate degree
5
7.0%
Employment status
Unemployed
17
24.0%
Employed (part-time or full-time)
43
60.6%
Stay-at-home parent
8
11.3%
Student
Marital status
Married or living common law
51
71.8%
Widowed
1
1.4%
Separated
6
8.5%
Divorced
5
7.0%
Single
6
8.5%
Spouse or Partner of Primary Caregiver
Highest educational attainment
Less than secondary school graduation
7
9.9%
Secondary school diploma or equivalent
9
12.7%
Vocational training
7
9.9%
College or university diploma or degree
27
38.0%
Graduate degree
7
9.9%
Employment status
Unemployed
5
7.0%
Employed (part-time or full-time)
49
69.0%
Stay-at-home parent
3
4.2%
Student
-
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Frequency
Household
Household size
4 (3, 5)c
Annual household income before taxes (CAD)
$14,999 and under
1
$15,000 to $34,999
7
$35,000 to $49,999
7
$50,000 to $74,999
9
$75,000 to $99,999
14
$100,000 and over
24
a
Primary caregiver describes the parent who completed the questionnaire
b
Data are mean  standard deviation; (range)
c
Data are median (interquartile range); (range)

Percentage
(2, 9)c
1.4%
9.9%
9.9%
12.7%
19.7%
33.8%

82
Table 4.4. Descriptive statistics for the Pediatric Quality of Life InventoryTM (PedsQLTM)
Multidimensional Fatigue Scale by child self-report and parent proxy-report
Duchenne Muscular Dystrophy Sample
Healthy Samplea
N
Mean 
Mean 
Median (IQR)
Range
N
SD
SD
Child Self-Report
66 71.6  15.2 69.4 (62.5, 81.9) (25, 100)
Total fatigue
82.2  12.3
66 70.2  19.7 70.8 (58.3, 83.3)
General fatigue
(0, 100)
86.4  13.1
157
66 74.0  17.5 75 (64.6, 87.5)
Sleep/rest fatigue
(8.3, 100)
77.4  15.4
65
Cognitive fatigue
(0, 100)
70.9  23.0 70.8 (54.2, 91.7)
82.8  16.3
Parent Proxy-Report
69 70.8  16.0 69.4 (58.3, 84.7) (37.5, 100)
Total fatigue
87.2  10.9
69 64.2  20.1 62.5 (45.8, 79.2) (25, 100)
General fatigue
88.4  11.7
157
69 76.9  18.0 79.2 (66.7, 91.7) (8.3, 100)
Sleep/rest fatigue
86.7  12.6
69 69.7  24.6 75 (54.2, 91.7)
Cognitive fatigue
(0, 100)
86.6  16.4
Abbreviations: N, sample size; SD, standard deviation; IQR, interquartile range.
a
From published data: Varni JW et al. Int J Ped Obes 2010;5:34–42.
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Table 4.5. Descriptive statistics for the Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional Fatigue Scale by age group
Median (IQR)
Mean  SD
Child Self-Report
Young children
10
72.2 (63.9, 88.9)
72.5  21.4
Total fatigue
Older children
23
69.4 (56.9, 81.9)
69.9  14.9
Adolescents
33
69.4 (65.3, 81.9)
72.5  13.6
Young children
10
83.3 (75, 91.7)
75.0  28.9
General fatigue
Older Children
23
66.7 (54.2, 87.5)
70.3  19.0
Adolescents
32
70.8 (56.3, 81.3)
68.6  17.1
Young children
10
79.2 (66.7, 91.7)
80.0  16.3
Sleep/rest fatigue
Older children
23
70.8 (62.5, 83.3)
72.9  15.3
Adolescents
33
75 (62.5, 87.5)
72.9  19.4
Young children
10
62.5 (41.7, 91.7)
62.5  31.2
Cognitive fatigue
Older children
23
62.5 (50, 87.5)
66.9  20.8
Adolescents
33
75 (62.5, 95.8)
76.1  21.1
Parent Proxy-Report
Young children
12
84.0 (51.4, 95.8)
74.8  23.8
Total fatigue
Older children
25
62.5 (56.9, 79.2)
67.3  16.3
Adolescents
32
71.5 (64.6, 81.3)
71.9 11.8
Young children
12
77.1 (54.2, 100)
75.0  25.6
General fatigue
Older children
25
58.3 (45.8, 75)
60.7  19.8
Adolescents
32
62.5 (47.9, 75)
62.9  17.1
Young children
12
89.6 (68.8, 100)
84.7  16.3
Sleep/rest fatigue
Older children
25
75 (62.5, 87.5)
77.0  16.6
Adolescents
32
77.1 (64.6, 89.6)
73.9  19.2
Young children
12
70.8 (37.5, 100)
64.6  34.2
Cognitive fatigue
Older children
25
58.3 (45.8, 91.7)
64.3  26.8
Adolescents
32
75 (62.5, 89.6)
75.8  16.8
Abbreviations: N, sample size; SD, standard deviation; IQR, interquartile range.
a
Young children, ages 4–7 years; older children, ages 8–12 years; adolescents, age 13–17 years.
b
Kruskal-Wallis tests were used to assess differences between age groups.
Age Groupa

N

Range
(25, 100)
(45.8, 98.6)
(44.4, 97.2)
(0, 100)
(25, 100)
(25, 100)
(50, 100)
(41.7, 100)
(8.3, 100)
(0, 100)
(29.2, 100)
(8.3, 100)
(37.5, 100)
(40.3, 100)
(51.4, 93.1)
(25, 100)
(25, 100)
(25, 91.7)
(58.3, 100)
(45.8, 100)
(8.3, 100)
(0, 100)
(0, 100)
(33.3, 100)

P-Valueb

0.66

0.23

0.45

0.12

0.32

0.13

0.21

0.28
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Table 4.6. Descriptive statistics for the Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional Fatigue Scale by ambulatory
status
Ambulatory Status
N
Median (IQR)
Range
P-Valuea
Mean  SD
Child Self-Report
Ambulant
39
72.2 (59.7, 83.3)
(25, 100)
71.6  16.3
Total fatigue
0.92
Non-ambulant
26
69.4 (65.3, 81.9)
(44.4, 97.2)
71.9  13.9
Ambulant
39
75 (62.5, 87.5)
(0, 100)
72.8  21.0
General fatigue
0.12
Non-ambulant
25
70.8 (54.2, 75)
(25, 100)
66.7  17.5
Ambulant
39
75 (62.5, 87.5)
(33.3, 100)
73.7  17.2
Sleep/rest fatigue
0.75
Non-ambulant
26
75 (66.7, 83.3)
(8.3, 100)
73.9  18.5
Ambulant
39
70.8 (50, 91.7)
(0, 100)
68.6  23.3
Cognitive fatigue
0.21
Non-ambulant
26
70.8
(58.3,
91.7)
(8.3,
100)
75.3  22.2
Parent Proxy-Report
Ambulant
42
70.8 (58.3, 84.9)
(37.5, 100)
71.0  18.0
Total fatigue
0.84
Non-ambulant
27
68.1 (58.3, 81.9)
(51.4, 93.1)
70.3  12.7
Ambulant
42
62.5 (45.8, 87.5)
(25, 100)
65.8  22.1
General fatigue
0.55
Non-ambulant
27
62.5 (45.8, 75)
(25, 87.5)
61.7  16.7
Ambulant
42
81.3 (66.7, 91.7)
(45.8, 100)
79.4  15.1
Sleep/rest fatigue
0.27
Non-ambulant
27
75 (62.5, 91.7)
(8.3, 100)
72.9  21.4
Ambulant
42
72.9 (50, 91.7)
(0, 100)
67.9  27.9
Cognitive fatigue
0.72
Non-ambulant
27
75
(58.3,
87.5)
(33.3,
100)
72.5  18.3
Abbreviations: N, sample size; SD, standard deviation; IQR, interquartile range.
a
Wilcoxin Rank Sum tests were used to assess differences between ambulant and non-ambulant individuals.
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Parent Proxy-Report

Table 4.7. Correlation analyses between child self-report and parent proxy-report Pediatric Quality of Life InventoryTM (PedsQLTM)
Multidimensional Fatigue Scale scores
Spearman’s Rank Correlation Coefficient (ρ)
N
P-Value
Child Self-Report
Total fatigue General fatigue Sleep/rest fatigue Cognitive fatigue
0.69
Total fatigue
64
<0.001
0.63
General fatigue
63
<0.001
0.50
Sleep/rest fatigue
64
<0.001
0.68
Cognitive fatigue
64
<0.001
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Table 4.8. Correlation analyses between child characteristics and Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional
Fatigue Scale scores by child self-report
Spearman’s Rank Correlation Coefficient (ρ)
N
P-Value
Total
General
Sleep/rest
Cognitive
fatigue
fatigue
fatigue
fatigue
Clinical Characteristics
Age (years)

0.01
66
0.92

-0.19
65
0.14

-0.06
66
0.62

0.23
66
0.07

Forced vital capacity (%)

0.29
40
0.07

0.34
39
0.03

0.15
40
0.35

0.03
40
0.87

Left ventricular ejection fraction (%)

0.00
42
0.99

0.10
41
0.52

-0.22
42
0.16

0.08
42
0.60

Child Self-Report or Parent Proxy-Report Measures
Physical Activity Questionnaire for Children and Adolescents

0.13
58
0.32

0.27
57
0.04

0.12
58
0.35

-0.06
58
0.67

Duchenne Muscular Dystrophy Functional Ability SelfAssessment Tool

0.05
64
0.67

0.30
63
0.02

-0.01
64
0.94

-0.13
64
0.31

Center for Epidemiological Studies Depression Scale for
Children

-0.46
66
<0.001

-0.30
65
0.02

-0.30
66
0.02

-0.46
66
<0.001
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Sleep Disturbance Scale for Children
Disorders of initiating and maintaining sleep

-0.54
51
<0.001

-0.37
50
0.008

-0.26
51
0.07

-0.49
51
<0.001

Sleep-related breathing disorders

-0.14
62
0.27

-0.33
61
0.009

-0.06
62
0.62

0.06
62
0.64

Disorders of Arousal

-0.35
62
0.005

-0.27
61
0.03

-0.13
62
0.32

-0.41
62
0.001

Sleep-wake transition disorders

-0.26
60
0.04

-0.26
59
0.05

-0.15
60
0.25

-0.14
60
0.28

Disorders of excessive somnolence

-0.34
58
0.009

-0.15
57
0.26

-0.33
58
0.01

-0.24
58
0.07

Sleep hyperhidrosis

-0.03
62
0.82

-0.12
61
0.37

0.15
62
0.26

-0.06
62
0.66

Total sleep disturbance symptoms

-0.42
46
0.003

-0.32
45
0.03

-0.30
46
0.04

-0.33
46
0.03

P-Values in bold are statistically significant at =0.05 two-sided level of significance.
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Table 4.9. Correlation analyses between child characteristics and Pediatric Quality of Life InventoryTM (PedsQLTM) Multidimensional
Fatigue Scale scores by parent proxy-report
Spearman’s Rank Correlation Coefficient (ρ)
N
P-Value
Total
General
Sleep/rest
Cognitive
fatigue
fatigue
fatigue
fatigue
Clinical Characteristics
Age (years)

0.06
69
0.62

-0.10
69
0.42

-0.18
69
0.15

0.20
69
0.10

Forced vital capacity (%)

0.12
40
0.48

0.22
40
0.17

0.07
40
0.68

-0.01
40
0.93

Left ventricular ejection fraction (%)

0.06
41
0.71

0.22
41
0.17

-0.07
41
0.68

0.02
41
0.89

Child Self-Report or Parent Proxy-Report Measures
Physical Activity Questionnaire for Children and Adolescents

0.09
57
0.49

0.16
57
0.24

0.18
57
0.17

-0.11
57
0.43

Duchenne Muscular Dystrophy Functional Ability SelfAssessment Tool

0.26
69
0.03

0.30
69
0.01

0.35
69
0.003

0.08
69
0.52

Center for Epidemiological Studies Depression Scale for
Children

-0.45
64
<0.001

-0.37
64
0.002

-0.35
64
0.005

-0.32
64
0.009
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Sleep Disturbance Scale for Children
Disorders of initiating and maintaining sleep

-0.53
55
<0.001

-0.36
55
0.008

-0.40
55
0.003

-0.46
55
<0.001

Sleep-related breathing disorders

-0.20
67
0.10

-0.14
67
0.24

-0.19
67
0.12

-0.17
67
0.18

Disorders of Arousal

-0.43
67
<0.001

-0.34
67
0.005

-0.27
67
0.03

-0.37
67
0.002

Sleep-wake transition disorders

-0.35
65
0.004

-0.29
65
0.02

-0.33
65
0.007

-0.28
65
0.02

Disorders of excessive somnolence

-0.42
63
<0.001

-0.41
63
<0.001

-0.58
63
<0.001

-0.12
63
0.35

Sleep hyperhidrosis

-0.16
67
0.20

-0.07
67
0.56

-0.11
67
0.39

-0.19
67
0.12

Total sleep disturbance symptoms

-0.51
50
<0.001

-0.45
50
0.001

-0.48
50
<0.001

-0.34
50
0.01

P-Values in bold are statistically significant at =0.05 two-sided level of significance.
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Table 4.10. Multivariable linear regression analyses with listwise deletion to predict child self-reported fatigue (N=41)
𝛽̂
(95% Confidence Interval)
P-Value
Dependent Variable
Independent Variables
Total fatigue
General fatigue Sleep/rest fatigue Cognitive fatigue
-0.84
-0.97
-0.28
-1.24
Sleep Disturbance Scale for Children
(-1.31, -0.38)
(-1.59, -0.35)
(-0.84, 0.27)
(-2.10, -0.39)
0.001
0.003
0.31
0.006
Physical Activity Questionnaire for Children and
Adolescents

2.50
(-3.08, 8.08)
0.37

3.08
(-4.44, 10.61)
0.41

4.39
(-2.28, 11.05)
0.19

0.35
(-9.95, 10.64)
0.95

Duchenne Muscular Dystrophy Functional Ability
Self-Assessment Tool

-0.18
(-0.81, 0.45)
0.57

0.22
(-0.62, 1.07)
0.59

-0.54
(-1.29, 0.21)
0.15

-0.22
(-1.39, 0.94)
0.70

-0.32
-0.70
(-0.94, 0.30)
(-1.55, 0.14)
0.31
0.10
R2 (Adjusted)
0.38
0.39
P-Values in bold are statistically significant at =0.05 two-sided level of significance.

-0.01
(-0.75, 0.73)
0.97
0.02

-0.33
(-1.47, 0.82)
0.56
0.22

Center for Epidemiological Studies Depression Scale
for Children
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Table 4.11. Multivariable linear regression analyses with listwise deletion to predict parent proxy-reported fatigue (N=41)
𝛽̂
(95% Confidence Interval)
P-Value
Dependent Variable
Independent Variable
Total fatigue
General fatigue Sleep/rest fatigue Cognitive fatigue
-0.91
-1.08
-0.62
-1.03
(-1.36,
-0.46)
Sleep Disturbance Scale for Children
(-1.74, -0.42)
(-1.11, -0.13)
(-1.85, -0.21)
<0.001
0.002
0.01
0.02
-1.37
1.00
1.52
-6.64
Physical Activity Questionnaire for Children and
(-6.78, 4.04)
(-6.93, 8.93)
(-4.34, 7.38)
(-16.53, 3.24)
Adolescents
0.61
0.80
0.60
0.18
0.68
0.43
0.83
0.78
Duchenne Muscular Dystrophy Functional Ability
(0.07, 1.29)
(-0.46, 1.33)
(0.17, 1.49)
(-0.34, 1.90)
Self-Assessment Tool
0.03
0.34
0.02
0.17
-0.28
-0.38
-0.15
-0.30
Center for Epidemiological Studies Depression Scale (0.88, 0.32)
(-1.26, 0.50)
(-0.80, 0.50)
(-1.40, 0.79)
for Children
0.36
0.39
0.64
0.58
R2 (Adjusted)
0.44
0.32
0.32
0.18
P-Values in bold are statistically significant at =0.05 two-sided level of significance.
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Table 4.12. Multivariable linear regression analyses with multiple imputation using chained equations to predict
fatigue (N=71)
𝛽̂
(95% Confidence Interval)
P-Value
Dependent Variable
Independent Variable
Total fatigue
General fatigue Sleep/rest fatigue
-0.62
-0.73
-0.17
Sleep Disturbance Scale for Children
(-1.06, -0.18)
(-1.38, -0.09)
(-0.83, 0.49)
0.008
0.03
0.60

child self-reported

Cognitive fatigue
-0.94
(-1.58, -0.30)
0.005

Physical Activity Questionnaire for Children and
Adolescents

1.94
(-2.95, 6.83)
0.43

2.82
(-3.40, 9.04)
0.37

3.22
(-3.53, 9.96)
0.34

0.07
(-8.22, 8.35)
0.99

Duchenne Muscular Dystrophy Functional Ability
Self-Assessment Tool

0.29
(-0.26, 0.83)
0.29

0.84
(0.10, 1.58)
0.03

0.17
(-0.60, 0.94)
0.66

-0.13
(-0.99, 0.73)
0.76

Center for Epidemiological Studies Depression Scale
for Children

-0.77
(-1.17, -0.38)
<0.001

-0.80
(-1.32, -0.28)
0.003

-0.60
(-1.17, -0.03)
0.04

-0.93
(-1.54, -0.32)
0.004

P-Values in bold are statistically significant at =0.05 two-sided level of significance.
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Table 4.13. Multivariable linear regression analyses with multiple imputation using chained equations to predict parent proxy-reported
fatigue (N=71)
𝛽̂
(95% Confidence Interval)
P-Value
Dependent Variable
Independent Variables
Total fatigue
General fatigue Sleep/rest fatigue Cognitive fatigue
-0.66
-0.74
-0.39
-0.73
Sleep Disturbance Scale for Children
(-1.26, -0.06)
(-1.45, -0.03)
(-1.13, 0.34)
(-1.61, 0.15)
0.03
0.04
0.27
0.10
Physical Activity Questionnaire for Children and
Adolescents

-1.55
(-7.23, 4.12)
0.58

0.08
(-6.45, 6.62)
0.989

-0.47
(-6.90, 5.95)
0.88

-4.17
(-14.24, 5.91)
0.41

Duchenne Muscular Dystrophy Functional Ability
Self-Assessment Tool

0.79
(0.21, 1.38)
0.001

1.11
(0.35, 1.86)
0.005

1.19
(0.49, 1.90)
0.001

0.47
(-0.54, 1.48)
0.36

Center for Epidemiological Studies Depression Scale
for Children

-0.82
(-1.27, -0.37)
0.001

-0.91
(-1.44, -0.38)
0.001

-0.71
(-1.26, -0.16)
0.01

-0.98
(-1.79, -0.18)
0.02

P-Values in bold are statistically significant at =0.05 two-sided level of significance.
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Chapter 5
5

Discussion
To our knowledge, this is the first study to describe fatigue in children and adolescents

with Duchenne muscular dystrophy (DMD), from the perspective of patients and their
parents. Additionally, we have proposed a novel conceptual model of factors associated
with fatigue in children and adolescents with DMD, and tested associations of patient
characteristics with fatigue in this population. Our results demonstrated fatigue to be a
significant issue in children and adolescents with DMD, across age groups from early
childhood to adolescence, and across disease stages from the early ambulatory to late nonambulatory stages, highlighting the need for fatigue to be addressed in the routine clinical
care of affected boys. We have identified several factors associated with fatigue, which
have contributed to our understanding of the subjective experience of fatigue as a complex,
multi-causal and multidimensional phenomenon in paediatric DMD. Our findings
demonstrated greater sleep disturbance symptoms, greater depressive symptoms and lower
functional ability related to activities of daily living to be associated with greater fatigue in
children and adolescents with DMD. These findings warrant further investigation in the
development of evidence-based therapeutic strategies aimed at reducing fatigue and
improving health-related quality of life. This chapter discusses our results in the context of
existing literature and interprets key findings pertaining to each objective, while
highlighting their clinical and research implications.
5.1

Sample Characteristics
Our sample was composed of 71 children and adolescents with DMD between the

ages of 5–17 years, and included patients with DMD across all disease stages: early
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ambulatory, late ambulatory, early non-ambulatory and late non-ambulatory. Over half of
the patients in our sample were ambulatory and most were without known severe
respiratory or cardiac complications, which may cause concern about non-response bias
and whether participating patients were at a less severe disease stage than non-participating
patients. However, comparison of registry data of participating and non-participating
patients demonstrated that there were no significant differences between participating and
non-participating patients. Our sample was representative of DMD patients registered in
the Canadian Neuromuscular Disease Registry (CNDR) with respect to both clinical
characteristics (age, genetic mutation, musculoskeletal, respiratory and cardiac
characteristics, and clinical trial participation) and geographic region in Canada.
5.2

Objective 1: To describe subjective fatigue in children and adolescents with
DMD from patients’ and parents’ perspectives
Children and adolescents with DMD in our study experienced greater fatigue than

healthy children and adolescents from published data, from both patients’ and parents’
perspectives [117,118,179]. Child self-reported and parent proxy-reported total and general
fatigue scores of boys with DMD in our study were comparable to previously published
scores of a multicentre cohort of ambulant boys with DMD of ages 5–13 years in Italy [58].
Moreover, child self-reported and parent proxy-reported fatigue for children and
adolescents with DMD in our study were comparable to those for children and adolescents
with cancer from published data—for whom fatigue is recognized as a frequent and
debilitating symptom, warranting the development of the term cancer-related fatigue and
its diagnostic criteria [13,179,208–211].
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In our study, child self-reports and parent proxy-reports of fatigue were similar,
except for general fatigue, in which parents perceived their child’s level of general fatigue
to be worse than that perceived by the patient. The general fatigue domain of the PedsQLTM
Multidimensional Fatigue Scale (MFS) has been reported to be more related to patient
functional ability [58]. Parents may therefore attribute their child’s fatigue to functional
ability more so than patients themselves do. This is supported by our finding that patient
functional ability was more strongly associated with parent proxy-reported fatigue than
with child self-reported fatigue. Our results comparing patients’ and parents’ perceptions
of fatigue are in contrast with the literature, which demonstrate poor agreement between
child self-reported and parent proxy-reported fatigue. In previous studies of children and
adolescents with chronic health conditions, parents typically underestimated their child’s
level of fatigue [118,212–215]. Imperfect agreement between child self-reported and
parent proxy-reported internalizing symptoms, such as fatigue, has consistently been
documented across paediatric patient populations [216]. Discrepancies between patients’
and parents’ perceptions of fatigue may impact treatment decisions and ultimately, clinical
outcomes. Gaultney et al. reported greater discrepancy between child self-reported and
parent proxy-reported fatigue to be associated with more depressed mood in patients with
juvenile idiopathic arthritis [212].
Although our results demonstrated similar perceptions of fatigue by patients and
their parents, it is unclear whether this finding would translate to a clinical setting, where
parallel child self-report and parent proxy-report fatigue rating scales may not be used.
Hinds et al. demonstrated that paediatric oncology patients and their parents often use
different language to define and describe fatigue in a clinical setting [213], reaffirming the
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need for clinicians to assess both patients’ and parents’ perspectives of fatigue when
making treatment decisions [118,212]. It may be that in the case of a condition involving
progressive motor impairment with onset as young as infancy, like DMD, parents have a
greater appreciation of their child’s fatigue as they are more vigilant about their child’s
mobility and conscious of potential difficulties their son may encounter keeping up with
peers [217]. Parents’ expectations and observations of muscle weakness interfering with
their child’s daily activities may therefore foster a shared understanding of fatigue severity
between patients with DMD and their parents. Additional studies are required to draw firm
conclusions regarding agreement between child self-reported and parent proxy-reported
fatigue in the paediatric DMD population. Studies involving qualitative interviews and
focus groups with children and adolescents with DMD, and their parents, can enhance our
understanding of similarities and discrepancies between patients’ and parents’ perceptions
of fatigue [213].
We used age and ambulatory status to describe fatigue in children and adolescents
with DMD across different disease stages. No statistically significant differences in fatigue
were observed between young children (5–7 years of age), older children (8–12 years of
age) and adolescents (13–17 years of age), or between ambulant and non-ambulant
patients, by child self-report or parent proxy-report. Patients with DMD in our study
consistently experienced greater fatigue than their healthy peers when compared to
published data, by child self-report and parent proxy-report, across age groups and
ambulatory status [117,118,179]. Therefore, fatigue may be a prominent issue in paediatric
patients with DMD at all disease stages.
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Although not statistically significant, child self-reported and parent proxy-reported
total fatigue was greater for older children, compared with young children and adolescents.
Older children are typically in an ambulatory decline phase and may therefore experience
greater fatigue due to continued participation in physical activities that are becoming
progressively more challenging and exhausting over time. In a previous study, patients with
DMD using a wheelchair intermittently were more fatigued than patients not using a
wheelchair, suggesting that the time around transitioning to wheelchair use during the
ambulatory decline phase may be associated with greater fatigue [3]. In our study,
intermittent wheelchair users were also more fatigued than non-wheelchair users, although
differences were not statistically significant.
General fatigue and sleep/rest fatigue, which are reflective of the physical
component of fatigue [16], were more severe among older children and adolescents
compared with young children, whereas cognitive fatigue, which is reflective of the mental
component of fatigue [16], was more severe among young children and older children
compared with adolescents. Hinds et al. reported that children with cancer of ages 7–12
years emphasized physical fatigue, whereas adolescents with cancer of ages 13–18 years
emphasized a dynamic combination of physical and mental fatigue when describing their
fatigue during focus groups [213]. Greater general and sleep/rest fatigue in older children
and adolescents with DMD may be attributable to greater disease severity—particularly
muscle weakness and reduced functional ability, which are known risk factors for fatigue
in adult neuromuscular disorders [47,57]. Items in the cognitive fatigue domain of the
PedsQLTM MFS focus on problems with working memory, information retrieval and
attention—all of which improve with age [179,218]. Adolescents have better working and
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long term memory, shorter information processing speeds and longer attention spans
compared with young children and older children [218]. Greater cognitive fatigue in young
children and older children with DMD compared with adolescents may therefore be
attributable to normal age-related cognitive development. Similar trends were observed for
non-ambulant patients who are at a more severe disease stage and typically older than
ambulant patients, such that non-ambulant patients experienced greater general and
sleep/rest fatigue, and less cognitive fatigue than ambulant patients with DMD.
These findings have implications for potential therapeutic strategies for fatigue in
DMD, such that younger patients at early disease stages may benefit from therapies
targeting mental fatigue and older patients at late disease stages may benefit from therapies
targeting physical fatigue. However, to our knowledge, the minimal clinically important
differences for child self-reported and parent proxy-reported PedsQLTM MFS scores have
not yet been defined. Therefore, the clinical significance of trends described from our
findings are speculative and require further investigation.
5.3

To explore associations of patient characteristics with child self-report and
parent proxy-report measures of subjective fatigue in children and adolescents
with DMD.
Of the patient characteristics explored in our study, sleep disturbance symptoms

and depressive symptoms emerged as the strongest correlates of child self-reported and
parent proxy-reported fatigue. Functional ability emerged as a correlate of parent proxyreported fatigue more so than child self-reported fatigue. Physical activity level and clinical
characteristics including age, and musculoskeletal, respiratory and cardiac function were
not consistently associated with child self-reported or parent proxy-reported fatigue.
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Because sleep disturbances are frequent in children and adolescents with DMD
[72,219], and variations exist in the diagnostic assessment and management of sleep
disturbances in DMD across Canada [73], we hypothesized sleep disturbance symptoms to
be a potentially modifiable factor associated with fatigue. Our findings demonstrate that
greater sleep disturbance symptoms were significantly associated with greater fatigue from
both patients’ and parents’ perspectives. To our knowledge, the relationship between sleep
disturbances and fatigue has not been studied in paediatric neuromuscular disorders.
However, a link between sleep disturbances and fatigue has been established in adults with
myotonic dystrophy or multiple sclerosis, and other childhood chronic health conditions,
such as cancer [7,74–82].
Sleep-related breathing disorders, of both non-obstructive and obstructive origin,
are the most commonly documented sleep disturbances in DMD [71,72,111,219]. In our
study, symptoms of sleep-related breathing disorders did not emerge as a correlate of
fatigue. However, the accuracy of parent-reported symptoms of sleep-related breathing
disorders compared with objective sleep measurements is unclear [72]. Moreover,
symptoms such as restless sleep, nightmares, morning confusion and excessive daytime
sleepiness may be related to sleep-related breathing disorders, but were scored as items of
other domains in the Sleep Disturbance Scale for Children [201]. Therefore, the lack of
association between sleep disordered breathing and fatigue should be interpreted
cautiously.
Further examination of the relationship between sleep disordered breathing and
fatigue is warranted. The relationship between sleep disordered breathing and fatigue may
additionally be explored by examining the level of fatigue experienced by patients
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receiving non-invasive ventilation (NIV) for the management of respiratory failure, which
initially presents as nocturnal hypoventilation [53]. In our study, the two patients receiving
part-time (nocturnal) NIV experienced greater total fatigue, general fatigue and sleep/rest
fatigue compared with non-ventilated patients. However, this finding was only statistically
significant for parent proxy-reported sleep/rest fatigue. No clear relationship between fulltime (nocturnal and diurnal) NIV and fatigue was observed. Because the optimal time to
initiate NIV is still under debate [50], the absence of NIV may not accurately identify
patients without sleep disordered breathing. Therefore, no firm conclusions can be drawn
regarding the relationship between sleep-related breathing disorders or NIV and fatigue.
Moreover, our study was underpowered to detect differences in fatigue between ventilated
and non-ventilated patients. Symptoms related to disorders of initiating and maintaining
sleep, disorders of arousal, sleep-wake transition disorders and disorders of excessive
somnolence demonstrated the strongest associations with fatigue. Bloetzer et al. previously
reported disorders of initiating and maintaining sleep and disorders of excessive
somnolence to be prevalent in 29.7% and 10.9% of children and adolescents with DMD,
respectively [72]. Thus, clinical sleep evaluations in children and adolescents with DMD
should not be limited to detecting sleep-related breathing disorders, as other sleep
disturbances may be present and impact fatigue.
Consensus-based recommendations for sleep evaluations in DMD are included in
respiratory care recommendations by the American Thoracic Society and the international
DMD Care Considerations Working Group convened by the Centers for Disease Control
and Prevention [1,68,220]. The optimal time to screen for sleep disordered breathing in
DMD has not been determined, however annual polysomnography, or overnight pulse
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oximetry with continuous carbon dioxide monitoring (capnography) if polysomnography
is not available, is recommended starting from loss of ambulation and/or when clinically
indicated (i.e. at the onset of daytime symptoms of sleep disordered breathing or abnormal
pulmonary function tests) [68]. Polysomnography is a multi-parametric test used as a
diagnostic tool in sleep medicine to record physiological changes during sleep. The
polysomnogram monitors cerebral cortical activity (electroencephalogram), cardiac
activity (electrocardiogram), muscle activity (electromyogram), eye movements
(electrooculogram), respiratory airflow, thoracoabdominal movements, oximetry and
capnography [50].
Because oximetry with capnography has limited utility for detecting sleep
disturbances not associated with hypoxemia or hypercapnia, and because there is poor
correlation between daytime symptoms, abnormal pulmonary function and sleep
disturbances, a “polysomnography for all policy” has been proposed in the management of
children and adolescents with DMD [71,111]. However, polysomnography is costly and
not universally available across clinics [221]. In addition, because polysomnography
requires admission to a sleep laboratory and may result in the disruption of normal sleep
architecture and respiratory patterns, portable home monitoring has been proposed as an
alternative diagnostic tool for sleep disturbances in DMD. However, the validity of
portable home monitoring in paediatric neuromuscular disorders remains unclear
[41,71,221,222]. In Canada, routine polysomnography to assess for sleep disordered
breathing is ordered by approximately half of neurologists and respirologists caring for
children and adolescents with DMD [73]. Polysomnography is important for indicating the
need for timely intervention with NIV, which can reduce symptoms of sleep disordered
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breathing and potentially confer a beneficial effect on fatigue [223]. In addition to
determining the optimal time to screen for sleep disturbances using polysomnography,
further research is warranted to validate more affordable screening technologies in the
paediatric DMD population, such as portable home monitoring, and to determine sensitive
and specific daytime predictors of sleep disordered breathing [221,224,225].
In boys with DMD, sleep can be further complicated by disease-related,
psychological and social factors. Muscle weakness and the subsequent need to be turned
by a caregiver during the night has been reported to be associated with sleep disturbance
symptoms in boys with DMD [72]. Overnight use of ankle-foot orthotics or knee-anklefoot orthotics may cause further discomfort during sleep for some patients [55]. Although
the role of dystrophin in the central nervous system remains unclear, the absence of
dystrophin has been hypothesized to alter neuronal function, which may subsequently
impact sleep patterns [55]. Moreover, boys with DMD are at increased risk for emotional
and behavioural problems, including anxiety, depression and attention deficit hyperactivity
disorder (ADHD), which have been reported to contribute to sleep disturbances during
childhood and adolescence [91,226]. Parental exhaustion, sleep deprivation and poor
mental health, associated with caring for a child with DMD [227,228], can further
contribute to the vulnerability of these families and interfere with the development of
effective sleep hygiene practices in affected boys. Parents of children with DMD are at
higher risk for experiencing depression and lower self-esteem compared with parents of
healthy children [229]. Both maternal and paternal depression have been reported to be
associated with sleep disturbances in children [230]. Compromised parental mental health
may contribute to parenting inconsistency, which has been reported to be associated with

104
sleep disturbances in children with ADHD [231]. It is therefore imperative that
recommendations for the assessment and management of sleep disturbances in children
and adolescents with DMD are interdisciplinary and extend beyond sleep disordered
breathing to include other sleep disorders, as well as disease-related, psychological and
social factors.
Cognitive behavioural therapy (CBT) has been proposed as a treatment for
disorders of initiating and maintaining sleep. Concomitant treatment of sleep disturbances
and fatigue using CBT has been evaluated in adults with facioscapulohumeral dystrophy,
multiple sclerosis, chronic fatigue syndrome and traumatic brain injury, demonstrating
beneficial effects on sleep disturbances and fatigue, as well as comorbid depression
[103,143,232,233]. CBT has also been reported to reduce fatigue in adolescents with
chronic fatigue syndrome [234–236].
Our study demonstrated an association between greater depressive symptoms and
greater fatigue in children and adolescents with DMD from both patients’ and parents’
perspectives. This finding is consistent with studies that have examined the relationship
between depression and fatigue in other paediatric patient populations, such multiple
sclerosis, chronic fatigue syndrome and cancer [45,237–240]. Studies examining emotional
disturbances in children and adolescents with DMD are limited. However, there is evidence
to suggest boys with DMD are at increased risk for depression compared with their healthy
peers or other paediatric patient populations with physical disabilities, with older boys at
greater risk than young boys [55,91,241]. In a cross-sectional study of adults with DMD,
Pangalila et al. reported fatigue and affective disorders (depression and/or anxiety) to coexist in 24.1% of patients [120]. However, this finding is equivocal, as diagnoses of fatigue
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and affective disorders were made by dichotomizing self-reported scores of the Fatigue
Severity Scale and Hospital Anxiety and Depression Scale, respectively, as either
indicative or not indicative of clinical significance [120,242,243]. In addition to concerns
regarding sensitivity and specificity of these measures and the potential of misclassification
bias, dichotomization of continuous variables results in loss of information, produces
associations of lower magnitude and reduces statistical power [244–248].
Despite a strong association between depression and fatigue in chronic health
conditions, the causal relationships between depression and fatigue remain to be elucidated
[99,249]. Three causal hypotheses have been proposed in the literature relating to cancerrelated fatigue: (1) fatigue is caused by the illness, and treatment of the illness causes
depression, (2) fatigue develops in patients because of depression, or (3) no causal
relationship exists, and a third factor is the cause of both depression and fatigue. However,
demonstrating these relationships has proven to be a methodological challenge [249].
Understanding the causal relationship between fatigue and depression has clinical
implications for developing effective therapeutic strategies for fatigue. If depression and
fatigue are causally associated, a predominant effect in one direction may support a strategy
that targets either depression or fatigue first. Alternatively, a bidirectional causal
relationship may support a strategy that treats depression and fatigue as a symptom cluster.
For example, physical exercise has been proposed as a symptomatic therapy for both
depression and fatigue in patient populations, including children and adolescents with
physical disabilities [250,251]. Physical exercise has been evaluated as a treatment for
fatigue in children and adolescents with cancer with inconclusive results [252]. The
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feasibility of physical exercise as a treatment for fatigue may be limited in non-ambulant
boys with DMD due to functional limitations.
In our study, physical activity level was not associated with fatigue in children and
adolescents with DMD from patients’ or parents’ perspectives. This contrasts with findings
by Maher et al. in children and adolescents with physical disabilities, which included
neuromuscular disorders such as Charcot-Marie-Tooth disease, myotonia congenita and
myotubular myopathy [251]. Using an accelerometer to objectively measure physical
activity level, Maher et al. reported physical inactivity to be associated with fatigue in
children and adolescents with physical disabilities. Similarly, lower physical activity has
been reported to be associated with greater fatigue in children and adolescents with
multiple sclerosis [195]. It is possible that the Physical Activity Questionnaire for Children
and Adolescents used in our study did not adequately capture variability in the physical
activity level of children and adolescents with DMD [187]. Limited variability in the data
may have reduced the magnitude of correlation coefficients between physical activity level
and fatigue in our study [253].
Because most measures of physical activity level are intended for use in typically
developing children, there is a need for the development of feasible, valid and reliable
measures to assess physical activity level in children and adolescents with neuromuscular
disorders, which quantify both lower limb and upper limb activity [184]. The combined
use of subjective and objective measures has been recommended to achieve a better
understanding of physical activity level in children and adolescents with neuromuscular
disorders, as no single instrument can quantify all dimensions of physical activity [185].
Physical activity level is, at least in part, determined by functional ability in children and
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adolescents with DMD [184]. In our study, objective measures of musculoskeletal,
respiratory and cardiac function did not emerge as correlates of fatigue. Although
cardiomyopathy was associated with less cognitive fatigue from both patients’ and parents’
perspectives, this association may have been confounded by age. Onset of cardiomyopathy
in DMD typically occurs during adolescence and in our study, adolescents experienced less
cognitive fatigue compared with young children and older children. Lower functional
ability related to activities of daily living, however, was associated with greater fatigue
from parents’ perspective. Thus, parents may be more likely to perceive their child’s
fatigue as an outcome of or contributor to the progressive functional decline associated
with DMD more so than the patients themselves.
5.4

Strengths and Limitations
A strength of our study was that our sample was composed of children and

adolescents with DMD across disease stages. Moreover, the use of a national registry to
recruit patients facilitated the inclusion of patients from multiple clinics and regions within
Canada, thereby further enhancing the generalizability of our results. To our knowledge,
descriptive data of fatigue in paediatric DMD have only previously been published for
ambulant boys of ages 5–13 years in Italy, and only for total and general fatigue scores
measured using the PedsQLTM MFS [58].
The use of the PedsQLTM MFS was an additional strength of our study. A recently
published systematic review of instruments to assess fatigue in paediatric chronic health
conditions identified the PedsQLTM MFS to have the best evidence for strong psychometric
properties (reliability, content validity and hypothesis testing) in a range of paediatric
chronic health conditions across childhood, and as the only subjective fatigue measure with

108
robust evidence for use in young children [14]. Additionally, the use of a generic
instrument, the PedsQLTM MFS, enabled comparison of fatigue in children and adolescents
with DMD with healthy children and other patient populations to better comprehend the
severity of fatigue in paediatric DMD.
The assessment of fatigue from both patients’ and parents’ perspectives is also
considered to be strength of our study. A lack of agreement between child self-reported
and parent proxy-reported fatigue previously observed in other paediatric chronic health
conditions underscores the need to consider both patients’ and parents’ perspectives to
characterize fatigue during childhood and adolescence [14]. Understanding how parents’
perspectives compare with patients’ perspectives of fatigue is particularly important in a
clinical setting when a child is too young, too cognitively impaired or too ill to express
health concerns to their practitioner.
Our results should be interpreted considering several limitations. The crosssectional design of our study does not allow for temporality or causality to be established
regarding the associations explored between patient characteristics and fatigue in children
and adolescents with DMD. Additionally, a response rate of 36.8% and sample size of 71
may have resulted in a lack of statistical power to detect associations between some clinical
characteristics and fatigue. Although the Tailored Design Method was employed to
maximize our response rate to questionnaires, we were unable to implement a key
component of the Tailored Design Method due to privacy and confidentiality protocols of
the CNDR: personalization of contacts with eligible patients [177]. Personalization of
questionnaires and letters with a person’s name has been demonstrated to increase the
response rate of mailed paper questionnaires [177,254]. Personalization can reduce the
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social distance between the researcher and eligible patient, reduce the likelihood of a survey
request being ignored using the rationale that others will respond, establish authenticity of
the researcher and the study being conducted, and ultimately, establish trust between the
researcher and eligible patient—all of which should increase the response rate [177].
However, the CNDR does not allow for identification of eligible patients or for
investigators to contact eligible patients directly.
No differences in registry data were observed between participating and nonparticipating patients, demonstrating that our sample was representative of children and
adolescents with DMD registered in the CNDR with respect to clinical characteristics and
geographical region. However, the CNDR only included patients from British Columbia,
Albert, Ontario and Quebec, with Ontario contributing most patients to the registry.
Therefore, it is unclear whether children and adolescents with DMD registered in the
CNDR are representative of all children and adolescents with DMD across Canada,
particularly in remote regions. This has important implications in the study of fatigue given
the variations in clinical practices that exist across Canada for the screening and
management of sleep disordered breathing in children and adolescents with DMD [73].
Moreover, it is unclear whether patients enrolled in the CNDR systematically differ from
patients with DMD not enrolled in the CNDR with respect to clinical characteristics.
Epidemiological data on DMD in Canada is limited. To our knowledge, no Canadian
population-based descriptive studies on DMD have been published to allow for
comparison. Selection bias may have been introduced if patients at a more severe disease
stage were more likely to decline invitations to enroll in the CNDR. Nevertheless, the use
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of the CNDR allowed for a more representative sample than would have been achieved
through patient recruitment from our neuromuscular clinic only.
In addition to discrepancies in care practices or clinical characteristics between
patients enrolled in the CNDR and patients with DMD not enrolled in the CNDR, selection
bias and non-response bias may have been introduced from behavioural, socioeconomic or
cultural factors. For example, patients and parents who are more knowledgeable and
vigilant about their health may be more motivated to enroll in the registry and participate
in research studies. Similarly, higher educational attainment and income are associated
with greater health literacy [255], which may ultimately result in greater motivation to
enroll in the registry and participate in research studies. Factors that may prevent patients
and parents from responding to questionnaires include difficulties reading and writing or
cognitive impairment. Patients’ and parents’ past experiences in research studies, whether
positive or negative, may have also influenced both enrollment in the registry and
participation in the current study.
An additional limitation associated with the CNDR is the possibility of outdated
patient medical histories in the registry database. Most clinical data included in the registry
were obtained from clinic visits between 2013 and 2016. However, the inclusion of a
patient medical information section in the parent questionnaire allowed us to crossreference registry data and parent-reported data related to major disease milestones, such
as loss of ambulation and initiation of NIV. Discrepancies between registry and parentreported ambulatory status and ventilatory status were observed for five and four
participating patients, respectively.
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It is also possible that child self-report and parent proxy-report measures were
subject to a degree of response bias, such as recall bias or social-desirability bias. In our
study, fatigue was assessed over a one-month recall period, as previous research evaluating
the accuracy of fatigue ratings across recall periods demonstrated that momentary
assessments of fatigue were often more highly correlated with ratings from a one-month
recall period compared with a seven-day recall period [256]. Given the difficulty of
recalling many days, as in the case of a one-month recall period, patients with a chronic
illness refer to beliefs based on their extensive experience with symptoms, which provide
a reasonably accurate estimate of average symptom levels. When asked to construct a rating
to represent the past seven days, patients may attempt to retrieve memories from the past
week, which are subject to cognitive heuristics that give disproportionate weight to peak
and most recent symptoms experienced, thereby decreasing accuracy [256]. Lastly,
because questionnaires were not completed in a supervised setting, we cannot be certain
that patients and parents independently completed their respective questionnaires, or that
parents did not interpret questions or answers for their child if assistance was provided.
Due to similarities between the constructs of sleep disturbance symptoms and
depressive symptoms, it is possible that the multivariable regression analyses conducted
were affected by multicollinearity. Multicollinearity occurs when two or more independent
variables in a multivariable regression model are moderately to highly correlated.
Multicollinearity can reduce the precision of regression coefficient estimates, as
demonstrated by large standard errors and wide confidence intervals, and consequently
increase the risk of a type II error (failure to reject a false null hypothesis) [257].

112
5.5

Implications of Findings and Future Directions
Our results have implications in both clinical and research settings. Our findings

contribute to the limited literature on fatigue in a broader paediatric patient population of
children and adolescents with neuromuscular disorders. We have identified fatigue to be a
prominent issue in children and adolescents with DMD across disease stages, from both
patients’ and parents’ perspectives. This finding emphasizes the need for healthcare
providers to become more familiar with fatigue in children and adolescents with DMD and
to engage in dialogue about fatigue with DMD patients and their caregivers. Regular
assessment of fatigue at routine clinic visits may provide clinicians with insight about the
onset and patterns of fatigue in relation to other clinical manifestations or changes in
function, and aid in the identification of individualized therapeutic targets for fatigue. For
example, an increase in fatigue may be observed around the time of transition into
wheelchair use, as affected boys struggle to maintain independent ambulation. To reduce
fatigue, clinicians may encourage more flexible wheelchair use by focusing on the potential
benefit of improved fatigue, and aim to shift patient and parent attitudes about the negative
milestone of wheelchair use by emphasizing wheelchair use as a rehabilitative practice for
improving mobility, rather than a loss of independence [258].
We developed a conceptual model of factors associated with fatigue in paediatric
DMD, and tested the associations between factors included in the model and fatigue. In
doing so, we have identified several factors that may be associated with fatigue in
paediatric DMD, which warrant further investigation. Although causal conclusions cannot
be made regarding the associations of sleep disturbance symptoms, depressive symptoms,
physical activity level, functional ability and clinical characteristics with fatigue, our study
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serves as a hypothesis-generating starting point in this novel area of research in paediatric
DMD. Our results identified sleep disturbance symptoms, depressive symptoms and
functional ability as potentially modifiable risk factors associated with fatigue, warranting
further attention in clinical settings and in future research aimed at developing evidencebased interventions for the management of fatigue in paediatric DMD. Studies evaluating
interventions for the treatment of fatigue in paediatric patient populations are limited and
have primarily been conducted in paediatric chronic fatigue syndrome or cancer
populations. CBT may be worth exploring as a therapy for fatigue in children and
adolescents with DMD as it can simultaneously target fatigue, sleep disturbance symptoms
and depressive symptoms. Moreover, it has demonstrated promising effects on fatigue in
adult neuromuscular disorders and paediatric chronic fatigue syndrome [143,233–236].
In designing and conducting our study, we have identified several methodological
challenges of studying fatigue and factors associated with fatigue in children and
adolescents with DMD. Here, we provide insights on how these obstacles can be addressed
or ameliorated in future studies. Although registries are intended to be representative of
certain patient populations and reflective of the clinical practices of healthcare providers
in certain geographical regions, registries are often associated with challenges, such as
difficulties with patient recruitment and retention, that can have profound consequences on
the validity of registry data [259]. The representativeness of our sample to our target
population of children and adolescents across Canada may have been improved with the
recruitment of additional neuromuscular clinics to the CNDR. At the registry level,
providing innovative nonfinancial incentives that meet the needs of decision-makers at
potential recruitment sites has been demonstrated to increase patient enrollment and
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subsequently improve the validity and generalizability of research facilitated through
registries [259].
Additional large-scale prospective cohort studies are required to characterize the
trajectory of fatigue in paediatric DMD and to determine causal relationships of sleep
disturbance symptoms, depressive symptoms, physical activity level, functional ability and
clinical characteristics with fatigue. In our study, sleep disturbance symptoms and
depressive symptoms were identified as potentially modifiable factors associated with
fatigue in children and adolescents with DMD, as these symptoms may be overlooked in
the routine management of DMD. Child self-report and parent proxy-report symptombased measures are easy to administer, and are associated with low participation burden.
However, measures of sleep disturbance symptoms and depressive symptoms provide
limited information on the associations of formal diagnoses of sleep disturbances and
depression with fatigue. To further understand these relationships, polysomnographic data
and psychiatric evaluations conducted by clinicians are required in future studies.
In the early research of cancer-related fatigue, many qualitative studies were
conducted to better comprehend the complex, multi-causal and multidimensional
subjective experience of fatigue [260–263]. A qualitative study of fatigue in children and
adolescents with DMD can provide unprecedented insight on the origin, severity, patterns
and impact of fatigue. Moreover, qualitative interviews with DMD patients and their
parents may facilitate our understanding of similarities and differences of how patients and
their parents define and perceive fatigue. A qualitative study of fatigue in children and
adolescents with DMD may also facilitate the identification of additional factors, and
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potential therapeutic targets, associated with fatigue that were not included in our proposed
model.
5.6

Conclusions
This is the first study to comprehensively describe fatigue in children and

adolescents with DMD from patients’ and parents’ perspectives, and to explore
associations of patient characteristics with fatigue in this population. Children and
adolescents with DMD experienced greater fatigue compared with their healthy peers, and
experience comparable levels of fatigue as children and adolescents with cancer, across all
disease stages from both patients’ and parents’ perspectives. Our findings underscore
fatigue as a prominent issue in paediatric DMD, which may be overlooked in the current
management of children and adolescents with DMD because of the lack of literature
describing the presentation and implications of fatigue in this population. Greater sleep
disturbance symptoms were associated with greater fatigue from patients’ and parents’
perspectives. Sleep disturbance symptoms may be overlooked in the management of
children and adolescents with DMD [71], and therefore warrant further investigation as a
potentially modifiable risk factor for fatigue in this population. Moreover, greater
depressive symptoms were associated with greater fatigue from patients’ and parents’
perspectives, and lower functional ability was associated with greater fatigue from parents’
perspective. Additional large-scale prospective cohort studies are required to establish
causality between these patient characteristics and fatigue in children and adolescents with
DMD, to facilitate the development of targeted therapeutic strategies to effectively reduce
fatigue and subsequently improve health-related quality of life.
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Appendices
Appendix A: Literature Review Search Strategy Terminology and Syntax
Table A.1. Database-specific terminology and syntax used in literature search strategy
Concept
MEDLINE
EMBASE
CINAHL
PsychINFO
Muscular
exp
muscular dystrophy/
(MH
SU.EXACT(“Muscular
Dystrophies/Spinal
Muscular
or becker muscular
“Muscular
Dystrophy”) or
Muscular Atrophy
dystrophies/ dystrophy/ or
Dystrophy”)
SU.EXACT(“Muscular
or exp
duchenne muscular
or or (MH
Disorders”)
Muscular
dystrophy/ or
“Muscular
atrophy,
dystrophinopathy/ or Dystrophy,
spinal/
emery dreifuss
Duchenne+”)
muscular dystrophy/
or (MH
or
“Muscular
facioscapulohumeral Atrophy,
muscular dystrophy/
Spinal+”)
or limb girdle
muscular dystrophy/
or progressive
muscular dystrophy/
or exp spinal
muscular atrophy/
Fatigue
exp fatigue/ fatigue/
(MH “Mental SU.EXACT(“Fatigue”)
Fatigue”) OR
(MH
“Fatigue”)
Search Limits
Full text
Human
English Language
Total Citations
404
356
47
209

Keywords
Muscular dystroph*
or dystrophinopath*
or duchenne muscular
dystrophy or becker
muscular dystrophy or
emery dreifuss
muscular dystrophy or
facioscapulohumeral
muscular dystrophy or
limb girdle muscular
dystrophy or spinal
muscular atrophy or
spinal muscle atrophy

Fatigue or fatigability
or tired*

-

1,016
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Appendix B: Literature Review Study Selection

Figure B.1. Flowchart of study selection for literature review
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Appendix C: Research Ethics Board Approval Notice
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Appendix D: Canadian Neuromuscular Disease Registry Affiliate Clinics
Table D.1. Current and former paediatric neuromuscular clinics participating in the
Canadian Neuromuscular Disease Registry
City
Clinical Sites
Academic Affiliation
Current
Vancouver, BC British Columbia Children’s
University of British
Hospital
Columbia
Calgary, AB
Alberta Children’s Hospital
University of Calgary
Toronto, ON
Holland Bloorview Kids
University of Toronto
Rehabilitation Hospital
London, ON
Thames Valley Children’s Centre
Western University
Ottawa, ON
Children’s Hospital of Eastern
University of Ottawa
Ontario
Kingston, ON
Child Development Centre, Hotel
Queen’s University
Dieu Hospital
Montreal, QC
Montreal Children’s Hospital
McGill University
Halifax, NS
IWK Health Centre
Dalhousie University
Former
Mississauga,
ErinoakKids Centre for Treatment
McMaster University
ON
and Development
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Appendix E: Letter of Information
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Appendix F: Assent Letter
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Appendix G: Thank-You Postcard
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Appendix H: Follow-up Reminder Letter
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Appendix I: PedsQLTM Multidimensional Fatigue Scale (Child Self-Report)
In the past ONE month, how much of a problem has this been for you…
GENERAL FATIGUE (problems with…)
1. I feel tired

0

Almost
Never
1

3

Almost
Always
4

2. I feel physically weak (not strong)

0

1

2

3

4

3. I feel too tired to do things that I like to do

0

1

2

3

4

4. I feel too tired to spend time with my friends

0

1

2

3

4

5. I have trouble finishing things

0

1

2

3

4

6. I have trouble starting things

0

1

2

3

4

Never

Sometimes
2

Often
3

Almost
Always
4

SLEEP/REST FATIGUE (problems with…)

Never

Sometimes
2

Often

1. I sleep a lot

0

Almost
Never
1

2. It is hard for me to sleep through the night

0

1

2

3

4

3. I feel tired when I wake up in the morning

0

1

2

3

4

4. I rest a lot

0

1

2

3

4

5. I take a lot of naps

0

1

2

3

4

6. I spend a lot of time in bed

0

1

2

3

4

Never

Almost
Never

Sometimes

Often

Almost
Always

1. It is hard for me to keep my attention on
things

0

1

2

3

4

2. It is hard for me to remember what people
tell me

0

1

2

3

4

3. It is hard for me to remember what I just
heard

0

1

2

3

4

4. It is hard for me to think quickly

0

1

2

3

4

5. I have trouble remembering what I was just
thinking

0

1

2

3

4

6. I have trouble remembering more than one
thing at a time

0

1

2

3

4

COGNITIVE FATIGUE (problems with…)
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Appendix J: PedsQLTM Multidimensional Fatigue Scale (Parent Proxy-Report)
In the past ONE month, how much of a problem has this been for your child…
GENERAL FATIGUE (problems with…)
7. Feeling tired

0

Almost
Never
1

8. Feeling physically weak (not strong)

0

1

2

3

4

9. Feeling too tired to do things that he/she
likes to do

0

1

2

3

4

10. Feeling too tired to spend time with his/her
11. friends
Trouble finishing things

0

1

2

3

4

0

1

2

3

4

12. Trouble starting things

0

1

2

3

4

Never

Sometimes
2

Often
3

Almost
Always
4

SLEEP/REST FATIGUE (problems with…)

Never

Sometimes
2

Often
3

Almost
Always
4

7. Sleeping a lot

0

Almost
Never
1

8. Difficulty sleeping through the night

0

1

2

3

4

9. Feeling tired when he/she wakes up in the
morning

0

1

2

3

4

10. Resting a lot

0

1

2

3

4

11. Taking a lot of naps

0

1

2

3

4

12. Spending a lot of time in bed

0

1

2

3

4

Never

Sometimes
2

Often
3

Almost
Always
4

COGNITIVE FATIGUE (problems with…)
7. Difficulty keeping his/her attention on things

0

Almost
Never
1

8. Difficulty remembering what people tell
him/her

0

1

2

3

4

9. Difficulty remembering what he/she just
heard

0

1

2

3

4

10. Difficulty thinking quickly

0

1

2

3

4

11. Trouble remembering what he/she was just
thinking

0

1

2

3

4

12. Trouble remembering more than one thing
at a time

0

1

2

3

4
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Appendix K: Physical Activity Questionnaire for Children
We are trying to find out about your level of physical activity from THE LAST 7 DAYS (IN THE
LAST WEEK). This includes sports or dance that make you sweat or make your legs or arms feel
tired, or games that make you breathe hard, like tag, skipping, running, climbing, and others.
We understand that the mobility and strength of children with Duchenne muscular dystrophy may
be limited and may prevent you from participating in physical activities to the same extent as your
peers. However, we are interested in any and all activities that you consider to be physically active.
Remember:
1. There are no right and wrong answers—this is not a test
2. Please answer all the questions as honestly and accurately as you can—this is very
important.

1. Physical activity in your spare time: Have you done any of the following activities in the past 7
days (last week)? If yes, how many times? (Check only one box per row.)
7 times
No
1–2
3–4
5–6
or more
Skipping
Rowing/canoeing
In-line skating
Tag
Walking for exercise
Bicycling
Jogging or running
Aerobics
Swimming
Baseball, softball
Dance
Football
Badminton
Skateboarding
Soccer
Street hockey
Basketball
Ice skating
Cross-country skiing
Ice hockey/ringette
Other:
____________________
____________________
2. In the last 7 days, during your physical education (PE) classes, how often were you very active
(playing hard, running, jumping, throwing)? (Check one only.)
I don’t do PE
Hardly ever
Sometimes
Quite often
Always
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3. In the last 7 days, what did you do most of the time at recess? (Check one only.)
Sat down (talking, reading, doing schoolwork)
Stood around or walked around
Ran or played a little bit
Ran around or played quite a bit
Ran or played hard most of the time
4. In the last 7 days, what did you normally do at lunch (besides eating lunch)? (Check one only.)
Sat down (talking, reading, doing schoolwork)
Stood around or walked around
Ran or played a little bit
Ran around or played quite a bit
Ran or played hard most of the time
5. In the last 7 days, on how many days right after school, did you do sports, dance, or play games
in which you were very active? (Check one only.)
None
1 time last week
2 or 3 times last week
4 times last week
5 times last week
6. In the last 7 days, on how many evenings did you do sports, dance, or play games in which you
were very active? (Check one only.)
None
1 time last week
2 or 3 times last week
4 or 5 times last week
6 or 7 times last week
7. On the last weekend, how many times did you do sports, dance, or play games in which you
were very active? (Check one only.)
None
1 time
2 or 3 times
4 or 5 times
6 or more times
8. Which one of the following describes you best for the last 7 days? Read all five statements before
deciding on the one answer that describes you.
All or most of free time was spent doing things that involve little physical
effort
I sometimes (1–2 times last week) did physical things in my free time
(e.g. played sports, went running, swimming, bike riding, did aerobics)
I often (3–4 times last week) did physical things in my free time
I quite often (5–6 times last week) did physical things in my free time
I very often (7 or more times last week) did physical things in my free
time
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9. Mark how often you did physical activity (like playing sports, games, doing dance, or any other
physical activity) for each day last week.
Very
None
Little bit
Medium
Often
often
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
10. Were you sick last week, or did anything prevent you from doing your normal physical activities?
(Check one.)
No
Yes
If yes, please specify in the box below:

11. Think about the past 7 days (last week) in comparison to other usual weeks. Were you more
physically activity last week than you normally would be in a typical week?
No
Yes
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Appendix L: Duchenne Muscular Dystrophy Functional Ability Self-Assessment
Tool
Please complete this section with your child. The questions below describe levels of activity for
arm function, mobility, transfers, and need for ventilatory support. The activities are intended to be
in order of difficulty and we would like you to check the box that best applies to your child’s current
level of function.
Question 1: Arm function

Select one

Can put an item, such as a book, onto a shelf above shoulder height
Can eat a meal without any help
Needs help to cut up food, but can feed and drink independently
Needs help to drink or feed self
Can pick objects up e.g. pen/money
Can move fingers e.g. press on mobile or other electronic device
Cannot move fingers
Question 2: Mobility

Select one

Walks independently long distances outdoors (more than 1 km)
Walks independently medium distances outdoors (less than 1 km)
Walks outdoors for short distances e.g. to car with or without help from a person
Walks indoors with or without help from a person, but requires wheelchair for
outdoors
Uses wheelchair indoors and outdoors
Uses wheelchair indoors and outdoors, but unable in some situations e.g. cold
weather or unable to control wheelchair without help

Question 3 to 7: Transfers

Can do
independently

Can do
with help

Needs to be lifted or
hoisted or cannot

Not ventilated

Ventilated
at night

Ventilated during day
and night

Get on and off the floor
Get in and out of a chair
Get in and out of bed
Get on and off the toilet
Go up and down stairs

Question 8: Ventilatory support
Ventilatory status
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Appendix M: Center for Epidemiological Studies Depressive Scale for Children
INSTRUCTIONS: Below is a list of the ways you might have felt or acted. Please check how much
you have felt this way during the past week.
DURING THE PAST WEEK

Not At
All

A
Little

Some

A Lot

Not At
All

A
Little

Some

A Lot

Not At
All

A
Little

Some

A Lot

Not At
All

A
Little

Some

A Lot

1. I was bothered by things that usually don’t bother me.
2. I did not feel like eating, I wasn’t very hungry.
3. I wasn’t able to feel happy, even when my family or
friends tried to help me feel better.
4. I felt like I was just as good as other kids.
5. I felt like I couldn’t pay attention to what I was doing.
DURING THE PAST WEEK
6. I felt down and unhappy.
7. I felt like I was too tired to do things.
8. I felt like something good was going to happen.
9. I felt like things I did before didn’t work out right.
10. I felt scared.
DURING THE PAST WEEK
11. I didn’t sleep as well as I usually sleep.
12. I was happy.
13. I was more quiet than usual.
14. I felt lonely, like I didn’t have any friends.
15. I felt like kids I know were not friendly or that they
didn’t want to be with me.
DURING THE PAST WEEK
16. I had a good time.
17. I felt like crying.
18. I felt sad.
19. I felt people didn’t like me.
20. It was hard to get started doing things.

167
Appendix N: Sleep Disturbance Scale for Children
INSTRUCTIONS: This questionnaire will allow to your doctor to have a better understanding of the
sleep-wake rhythm of your child and of any problems in his/her sleep behavior. Try to answer
every question; in answering, consider each question as pertaining to the past 6 months of the
child’s life. Please answer the questions by circling the number 1 to 5. Thank you very much for
your help.
1. How many hours of sleep
does your child get on most
nights?
2. How long after going to bed
does your child usually fall
asleep?

1
9-11 hrs

2
8-9 hrs

3
7-8 hrs

4
5-7 hrs

1
Less than
15 min

2
15-30 min

3
30-45 min

4
45-60 min

5
Less than
5 hrs
5
More than
60 min

5 Always (daily)
4 Often (3 or 5 times per week)
3 Sometimes (once or twice per week)
2 Occasionally (once or twice per month or less)
1 Never
3.
4.
5.
6.
7.

The child goes to bed reluctantly
The child has difficulty getting to sleep at night
The child feels anxious or afraid when falling asleep
The child startles or jerks parts of the body while falling asleep
The child shows repetitive actions such as rocking or head banging while
falling asleep
8. The child experiences vivid dream-like scenes while falling asleep
9. The child sweats excessively while falling asleep
10. The child wakes up more than twice per night
11. After waking up in the night, the child has difficulty to fall asleep again
12. The child has frequent twitching or jerking of legs while asleep or often
changes position during the night or kicks the covers off the bed.
13. The child has difficulty in breathing during the night
14. The child gasps for breath or is unable to breathe during sleep
15. The child snores
16. The child sweats excessively during the night
17. You have observed the child sleepwalking
18. You have observed the child talking in his/her sleep
19. The child grinds teeth during sleep
20. The child wakes from sleep screaming or confused so that you cannot
seem to get through to him/her, but has no memory of these events the
next morning
21. The child has nightmares which he/she doesn’t remember the next day
22. The child is unusually difficult to wake up in the morning
23. The child awakes in the morning feeling tired
24. The child feels unable to move when waking up in the morning
25. The child experiences daytime somnolence
26. The child falls asleep suddenly in inappropriate situations

1
1
1
1
1

2
2
2
2
2

3
3
3
3
3

4
4
4
4
4

5
5
5
5
5

1
1
1
1
1

2
2
2
2
2

3
3
3
3
3

4
4
4
4
4

5
5
5
5
5

1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4

5
5
5
5
5
5
5
5

1
1
1
1
1
1

2
2
2
2
2
2

3
3
3
3
3
3

4
4
4
4
4
4

5
5
5
5
5
5
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Appendix O: Patient Medical Information Section
We would like to ask you a few questions ask about some other health experiences your child
may have had.
1. Has your child ever been formally diagnosed with any of the following developmental
disorders?
No

Yes

Developmental Delay
A Learning Disability
Attention Deficit Disorder (ADD) or Attention Deficient Hyperactivity Disorder
(ADHD)
Autism, Pervasive Developmental Disorder (PDD) or Asperger’s Syndrome
Oppositional Defiant Disorder
Conduct Disorder
Depression
Anxiety
2. Does your child have any of the following health conditions?
No

Yes

Asthma
Cystic Fibrosis
Diabetes
Cerebral Palsy
Epilepsy
Cancer
Any other long-term health conditions. Please specify:

3. For each of the following, please provide 2 answers. Whether your child has a) ever needed
and b) ever received:
a) Ever
b) Ever
Needed
Received
No
Yes
No
Yes
Extra help with schoolwork (e.g. tutoring, working with a special
education resource teacher, having an Individualized Educational
Program). Please specify:

Placement in a special class for children with learning difficulties.
Speech-language therapy
Occupational therapy
Medication or therapy for behaviour problems. Please specify:

Medication or therapy for emotional problems (e.g. depression).
Please specify:
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4. Is your child currently involved in any clinical trials or other research studies for his Duchenne
muscular dystrophy?
No
Yes
5. Is your child able to walk?
No
Yes
If no, when did your child stop walking?
Less than 1 year ago
More than 1 year ago
6. Have there been any major changes in your child’s health within the last year (e.g. major
illness, hospitalization, etc.)?
No
Yes
If yes, please specify in the box below:
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Appendix P: Sociodemographic Information Section
1. Are you:
Male
Female

2. Who currently lives with your child? Please do not use any people’s names when completing
the table below:

Person

Their relationship to your child (e.g. Mom, Dad,
brother, sister, grandparent, aunt, uncle, friend,
roommate, partner/spouse)

Their
Age

Their Sex

1

Male

Female

2

Male

Female

3

Male

Female

4

Male

Female

5

Male

Female

6

Male

Female

7

Male

Female

8

Male

Female

3. Which of the following best describes your current work status? Check one box only.
Not working
due to my
child’s health

Not working
for “other”
reasons

Looking for
work outside
the home

Working fullor part-time
(either
outside the
home or at a
home-based
business)

Full time
homemaker

Student

Guardian

Other (please
explain on
the line
below)

4. What is your relationship to this child? Check one box only.
Biological
parent

Step parent

Foster parent

Adoptive
parent
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5. What is the highest grade of school you have completed?
Less than 8 years
8 to 12 years
Completed high school
Completed vocational/technical training
Completed college/university
Completed graduate school
Prefer not to disclose

6. What is your age?
7. What is your current marital status? Check one box only.
Married

Widowed

Divorced

Separated

Remarried

Never
married

8. Are you currently living with a spouse or partner?
No
Yes

If no, skip to question 11.

If yes, proceed to question 9.

9. Which of the following best describes your spouse’s/partner’s current work status? Check one
box only.

Not working
due to my
child’s health

Not working
for “other”
reasons

Looking for
work outside
the home

Working fullor part-time
(either
outside the
home or at a
home-based
business)

Full time
homemaker

10. What is the highest grade of school your spouse/partner has completed?
Less than 8 years
8 to 12 years
Completed high school
Completed vocational/technical training
Completed college/university
Completed graduate school
Prefer not to disclose

Student
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11. In which category is your total yearly household income before taxes? Check one box only.
Less than $5,000
$5,000 to $9,999
$10,000 to $14,999
$15,000 to $19,999
$20,000 to $24,999
$25,000 to $ 34,999
$35,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
$100,000 to $149,999
$150,000 to $200,000
Over $200,000
I don’t know

12. Thinking about your total family income, from which sources did your family receive income
during the past year? Check all that apply.
Wages and salaries
Income from self-employment
Family allowance (baby bonus)
Unemployment insurance or strike pay
Worker’s compensation
Old Age Security, Guaranteed Income Supplement, Canada or Quebec
Pension Plan, Retirement Pension Plan, Superannuation
Dividends and interest on bonds, deposits and saving certificates
Other government sources such as welfare, mother’s allowance, etc.
Other source(s). Please specify: ___________________________
Prefer not to disclose
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